Introduction {#s1}
============

DNA repair is crucial to maintain genomic integrity in the face of exogenous and endogenous challenges. Cells express an arsenal of DNA repair enzymes that maintain genomic integrity, and mouse mutants have revealed a critical role of DNA repair in both organismic ageing and disease ([@bib50]; [@bib64]). In addition, there is now compelling evidence that DNA repair enzymes function not only in lesion control but have been co-opted in epigenetic gene regulation via active DNA demethylation ([@bib7]; [@bib87]; [@bib113]). The best understood active demethylation mechanism involves TET dioxygenases, which iteratively oxidize the methyl group at C5 to yield 5-hydroxymethylcytosine (5hmC) ([@bib56]; [@bib98]), 5-formylcytosine (5fC) ([@bib49]; [@bib73]), and 5-carboxylcytosine (5caC) ([@bib38]; [@bib49]). Thymine DNA glycosylase (TDG) excises 5fC and 5caC and the ensuing abasic site intermediate is processed by BER to restore unmethylated C ([@bib23]; [@bib24]; [@bib38]; [@bib67]; [@bib88]; [@bib93]). The need for abasic site processing during active DNA demethylation therefore places BER enzymes center stage in epigenetic gene regulation.

Deficiency of the BER enzymes (e.g. TDG, APEX1, POLB, LIG3, XRCC1) can lead to abnormalities or lethality during embryogenesis ([@bib23]; [@bib24]; [@bib76]; [@bib96]; [@bib101]; [@bib114]), but the etiology of the physiological defects is often poorly understood. Notably, it is unclear if the phenotypic abnormalities are due to accumulating DNA damage or impaired DNA demethylation.

An example for BER enzymes acting both in lesion control and in epigenetic gene regulation are the endonuclease VIII-like glycosylases 1 and 2 (NEIL1 and NEIL2). These enzymes process oxidative DNA base lesions ([@bib5]; [@bib36]; [@bib37]; [@bib99]), but recently they have also been implicated in the machinery that removes 5-methylcytosine (5mC) from DNA during epigenetic DNA demethylation ([@bib69]; [@bib86]; [@bib91]; [@bib94]). NEIL1 and NEIL2 are bifunctional enzymes, which not only excise the damaged base but introduce a DNA single strand break via their AP lyase activity ([@bib36]; [@bib37]), while NEIL3 is mainly a monofunctional DNA glycosylase ([@bib57]). NEIL1 is involved in prereplicative repair during S-phase ([@bib40]), and NEIL2 preferentially processes oxidized bases from transcribing genes via transcription-coupled BER ([@bib6]). During epigenetic DNA demethylation NEIL1 and NEIL2 cooperate with TDG to excise oxidized 5mC intermediates generated by TET enzymes ([@bib86]; [@bib91]).

Mice deficient of NEIL1 are viable but display metabolic syndrome and brain dysfunction ([@bib14]; [@bib82]; [@bib105]). *Neil2* null mice are also viable but are susceptible to inflammation ([@bib16]), while Neil2-deficient frog embryos display neural crest defects ([@bib86]). This raises the question why and how does a defect in NEIL DNA glycosylases lead to these diverse and tissue-specific phenotypes? Both epigenetic regulation and DNA damage can, in principle, impact neural crest development ([@bib46]; [@bib85]; [@bib89]), thus what is the relative contribution of oxidative lesion control and epigenetic DNA demethylation to the NEIL phenotypes?

To address these questions we have investigated Neil-deficient *Xenopus* embryos and created and characterized seven mouse embryonic stem cell (mESC) lines deficient for *Neil1,2,3* (triple and single knockouts), *AP-endonuclease 1* (*Apex1*), *Thymine DNA glycosylase* (*Tdg*) and *Neil1/Tdg*. We describe a mechanism where NEIL-deficiency elicits an oxidative stress-induced, TP53-dependent DNA damage response (DDR), which induces apoptosis and impairs early cNCC specification. We show that *Neil1-* and *Neil2*-deficiency leads to accumulation of oxidative DNA damage in mitochondria. Our work demonstrates how impaired removal of oxidative lesions can lead to a selective lineage defect during embryonic development. Our study contributes to the understanding of aberrant cNCC development, the root cause of congenital craniofacial malformations ([@bib111]).

Results {#s2}
=======

Neil2-deficiency induces a Tp53 DNA damage response in *Xenopus* embryos {#s2-1}
------------------------------------------------------------------------

We showed previously that in *Xenopus* embryos knockdown of Neil2 with an antisense morpholino oligonucleotide (*neil2* MO) induces head and tail abnormalities at tailbud stage, which are caused by impaired cranial neural crest cell (cNCC) specification at neurula stage ([@bib86]). Of note, MOs are the loss-of-function approach of choice in model systems with large maternal stores of mRNA such as *Xenopus*, which can be targeted by MOs but not by for example TALEN or CRISPR/Cas9 approaches ([@bib10]; [@bib27]; [@bib28]; [@bib83]). The specificity of the *neil2* MO had been documented ([@bib86]) i) by phenocopy with a second non-overlapping morpholino, and ii) by rescue of the head and tail abnormalities with orthologous human *NEIL2* mRNA, which was not targeted by *neil2* MO ([Figure 1A](#fig1){ref-type="fig"}).

![Neil2 protects against a Tp53 DNA damage response-induced apoptosis in *Xenopus* neuroectoderm.\
(**A**) Phenotypes at stage 32 of *Xenopus leavis* embryos injected at one-cell stage with control- or *neil2* MO (left). Human *NEIL2* or bovine *Preprolactin* (control) mRNA was co-injected for rescue experiments (right). Scale bars, 500 µm. (**B**) Left, representative stainings of cranial cartilage of stage 45 embryos unilaterally injected with control or *neil2* MO, and control or human *NEIL2* mRNA for rescue purpose as indicated. PQ, palatoquadrate cartilage; ME, Meckel's cartilage; CE, ceratohyal cartilage; BR, branchial cartilage. Arrow indicates cartilage defects in Neil2 morphants. Scale bars, 500 µM. Right, quantification of embryo malformations (n = 15, 21, 20 and 15 embryos per group, from left to right). (**C**) Quantification of differentially expressed genes at stage 23 of *neil2* MO-injected embryos. (**D**) Pathway enrichment analysis of *neil2* MO upregulated genes. Dashed line indicates the significance threshold FDR = 0.05. (**E**) Western blot for total Tp53 and phosphoserine (pS345) Chk1 in dissected stage 14 neural plates of control and *neil2* MO-injected embryos. Alpha (a-) Tubulin served as loading control. Molecular weight of marker proteins \[x10^−3^\] is indicated on the left. Note that *X. laevis* Tp53 migrates at \~43 kDa. (**F**) qPCR expression analysis of *tp53* and Tp53 target genes in control- and *neil2* MO-injected embryos at stage 14. Expression of examined genes was normalized to *h4* and is presented relative to mRNA levels in control MO-injected embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (**G**) Western blot for pS345 Chk1 and NEIL2 in neural plates from control and *neil2* MO-injected stage 14 embryos co-injected with control or human *NEIL2* mRNA. Alpha (a-) Tubulin served as loading control. (**H**) Western blot for phosphoserine (pS10) histone H3 in neural plates from control and *neil2* MO-injected embryos at stage 15. Total histone H3 served as loading control. (**I**) Western blot analysis for Caspase-3 in dissected non-neural tissue and neural plates from control and *neil2* MO-injected stage 14 embryos co-injected with control and human *NEIL2* mRNA. Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows). (**J**) TUNEL (apoptosis) assay of stage 16 embryos injected unilaterally with *neil2* MO and *lacZ* lineage tracer (TUNEL, dark blue speckles; *lacZ*, light blue speckles). Scale bars, 200 µM. Right, quantification of TUNEL signal (n = 7 and 10 embryos per group, from left to right).](elife-49044-fig1){#fig1}

Proper differentiation of cNCCs is crucial for the development of craniofacial cartilage and bone structures ([@bib85]). Indeed, Alcian blue staining of head cartilage in *neil2* MO-injected embryos (single blastomere injection at 2-cell stage) revealed head cartilage, notably branchial cartilage defects at tadpole stage ([Figure 1B](#fig1){ref-type="fig"}), which were rescued by simultaneous injection of human *NEIL2* mRNA ([Figure 1B](#fig1){ref-type="fig"}).

To gain insight into the underlying mechanism leading to the cNCC phenotype, we microinjected *Xenopus* embryos with *neil2* MO and carried out RNA-seq gene expression profiling at early tailbud stage ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Differential expression analysis yielded a similar number of a few hundred up- and downregulated genes ([Figure 1C](#fig1){ref-type="fig"}). Interestingly, pathway enrichment analysis revealed significant results only for the upregulated genes with the top hits 'Tp53 pathway' and 'Tp53 pathway feedback loops' suggestive of a DNA damage response (DDR) ([Figure 1D](#fig1){ref-type="fig"}). Indeed, protein levels of both Tp53 and its upstream regulator phospho-Chk1 (pChk1) were induced in neural plates of Neil2 morphants, indicative for a DDR ([Figure 1E](#fig1){ref-type="fig"}). RT-qPCR confirmed upregulation of *tp53* and its target genes, including *ccng1*, *eda2r*, *aen*, and *riok3* ([Figure 1F](#fig1){ref-type="fig"}). Furthermore, co-injection of human *NEIL2* mRNA rescued induced pChk1 in Neil2 morphants, ruling out an unspecific Tp53-response to MO injection ([Figure 1G](#fig1){ref-type="fig"}). Notably, human *NEIL2* mRNA also reduced basal pChk1 levels.

The DDR in Neil2 morphants induced direct Tp53 targets characteristic for apoptosis (e.g. *eda2r*, *aen*). Apoptosis is linked to cNCC developmental defects since ablation of Tp53 and concomitant block of apoptosis suppress cranial facial abnormalities in *Tcof1* mouse mutants ([@bib51]). Indeed, while cell proliferation seemed unaffected in *neil2* MO-injected embryos as judged by phospho-histone H3 levels ([Figure 1H](#fig1){ref-type="fig"}), we observed elevated Caspase-3 cleavage in dissected neural plates but less in non-neural tissue ([Figure 1I](#fig1){ref-type="fig"}), indicative of cNCC-specific apoptosis in Neil2 morphants. Consistently, human *NEIL2* mRNA injection in Neil2 morphants rescued elevated Caspase-3 cleavage to endogenous levels, corroborating the specificity of the *neil2* MO-induced apoptosis in neural plates. Human *NEIL2* mRNA injection also decreased basal levels of cleaved Caspase-3, both in neural plates and non-neural tissue ([Figure 1I](#fig1){ref-type="fig"}), suggesting that elevated *Neil2* expression protects against apoptosis in whole embryos. Whole mount TUNEL assay of unilaterally *neil2* MO-injected embryos confirmed elevated apoptosis by *Neil2*-deficiency in stage 16 embryos ([Figure 1J](#fig1){ref-type="fig"}). We conclude that Neil2 protects against Tp53-mediated cell apoptosis in *Xenopus* embryos, notably in neural plate tissue.

Intrinsic apoptosis triggers malformations in Neil2-deficient *Xenopus* embryos {#s2-2}
-------------------------------------------------------------------------------

To test if the phenotypic malformations in Neil2-morphants are related to elevated apoptosis, we blocked the apoptosis pathway by co-injection with *bcl2l1* mRNA. *Bcl2l1* is a *Xenopus* homologue of mammalian BCL2, an anti-apoptotic factor acting downstream of TP53 ([@bib41]; [@bib103]). Importantly, *bcl2l1* overexpression substantially reduced phenotypic abnormalities of Neil2 morphants ([Figure 2A](#fig2){ref-type="fig"}), and rescued elevated cleaved Caspase-3 levels in a dose-dependent manner ([Figure 2B](#fig2){ref-type="fig"}). As expected, *bcl2l1* expression had no effect on endogenous nor induced Tp53 protein levels ([Figure 2B](#fig2){ref-type="fig"}).

![Malformations in Neil2-deficient *Xenopus* embryos are mediated by intrinsic apoptosis.\
(**A**) Top, representative phenotypes at stage 32 of *Xenopus laevis* embryos injected at one-cell stage with control- or *neil2* MO (bottom). *Xenopus bcl2l1* or bovine *Preprolactin* (control) mRNA was co-injected for rescue purpose. Scale bars, 500 µm. Bottom, quantification of embryo malformations (n = 17, 23, 24 and 14 embryos per group, from left to right). (**B**) Western blot for Caspase-3 (top) and Tp53 (bottom) in neural plates from control and *neil2* MO-injected stage 14 embryos co-injected with control or increasing amounts of *bcl2l1* mRNA (0.5, 1 and 2 ng). Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows). Molecular weight of marker proteins \[x10^−3^\] is indicated on the left. (**C**) qPCR expression analysis of mitochondrial (mt) genes in control- and *neil2* MO-injected embryos at stage 14. Expression of mt-genes was normalized to *h4* and is presented relative to mRNA levels in control MO-injected embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each).](elife-49044-fig2){#fig2}

BCL2 regulates the intrinsic apoptosis pathway that is associated with mitochondria and results in mitochondrial dysfunction. Upregulation of mitochondrial (mt) gene expression is a characteristic response to mitochondrial dysfunction ([@bib39]; [@bib80]). Indeed, we observed increased expression of *mt-Nd1,4* and *5* (*NADH dehydrogenase 1,4* and *5*) and *mt-co3* (*cytochrome c oxidase III*) in Neil2-morphant whole embryos, supporting ongoing intrinsic apoptosis and mitochondrial dysfunction ([Figure 2C](#fig2){ref-type="fig"}).

Oxidative stress causes neural crest defects in Neil2-deficient *Xenopus* embryos {#s2-3}
---------------------------------------------------------------------------------

What leads to the induction of a Tp53 DDR in Neil2 morphants? NEIL2 processes oxidative base lesions induced by reactive oxygen species (ROS), such as 8-oxoguanine (8oxoG), 5-hydroxyuracil (5hU), thymine glycol, and the formamidopyrimidines FapyG and FapyA ([@bib34]; [@bib50]), suggesting that accumulation of ROS DNA damage may account for embryonic abnormalities in Neil2-deficient *Xenopus* embryos. We therefore analyzed if *Xenopus* embryos are competent to mount a DDR following oxidative damage and if a DDR results in developmental abnormalities. Embryo treatment with the ROS producer pyocyanin ([@bib117]) upregulated Tp53 and pChk1 protein ([Figure 3A](#fig3){ref-type="fig"}), induced expression of *tp53* and its target genes ([Figure 3B](#fig3){ref-type="fig"}), and elevated Caspase-3 cleavage ([Figure 3C](#fig3){ref-type="fig"}). Moreover, pyocyanin-treated embryos phenocopied Neil2 morphants, displaying similar head and tail abnormalities ([Figure 3D](#fig3){ref-type="fig"}). Neurula stage embryos showed cNCC specification defects, where the cNCC markers *sox10*, *twist*, and *snail2* were downregulated, while the markers *sox3* (pan-neural), *en2* (midbrain), and *rx1* (eye) were unaffected ([Figure 3E](#fig3){ref-type="fig"}). Elevated ROS levels sensitized Neil2 morphants since pyocyanin treatment of embryos injected with a sub-critical dose of *neil2* MO, which alone did not yield abnormalities, elicited exacerbated abnormalities ([Figure 3F](#fig3){ref-type="fig"}). We conclude that *Neil2*-deficiency and ROS damage induce a Tp53 DDR in *Xenopus* embryos, leading to cNCC defects.

![Oxidative stress causes neural crest defects in *Neil2*-deficient *Xenopus* embryos.\
(**A**) Western blot analysis for total Tp53 and pS345 Chk1 of stage 14 embryos cultivated in 25 µM pyocyanin or DMSO (solvent). Alpha (a-) Tubulin served as loading control. Molecular weight of marker proteins \[x10^−3^\] is indicated on the left. (**B**) qPCR expression analysis of *tp53* and Tp53 target genes in embryos at stage 14 cultivated in 25 µM pyocyanin or DMSO. Expression of examined genes was normalized to *h4* and is presented relative to mRNA level of DMSO treated embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (**C**) Western blot analysis for Caspase-3 of stage 14 embryos cultivated in 25 µM pyocyanin or DMSO (solvent). Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows). (**D**) Left, representative phenotypes of stage 32 embryos treated with 25 µM pyocyanin or DMSO (solvent). Right, quantification of embryo malformations (n = 25 and 15 embryos per group, from left to right). Scale bars, 500 µM. (**E**) Left, whole mount in situ hybridization of the indicated marker genes in stage 16 *Xenopus* embryos treated with 25 µM pyocyanin or DMSO (solvent). Right, quantification of embryo malformations \[n = 10 and 14 embryos per group for *sox10*; 2 × 11 (*twist*); 15 and 7 (*snail2*); 11 and 14 (*sox3*); 2 × 11 (*en2*); 15 and 20 (*rx1*), from left to right\]. Scale bars, 200 µM (**F**) Top, phenotypes of stage 39 embryos treated with 10 µM pyocyanin and injected with 15 ng/embryo of control and *neil2* MOs (subthreshold dose). Bottom, quantification of embryo malformations (n = 12, 11, 6 and 8 embryos per group, from left to right). Scale bars, 500 µM. (**G**) Top, phenotypes of stage 37 embryos injected with 40 ng/embryo of control and *neil2* MOs and treated with 100 µM Vitamin C. Bottom, quantification of embryo malformations (n = 16, 22, 33 and 10 embryos per group, from left to right). Scale bars, 500 µM.](elife-49044-fig3){#fig3}

Importantly, treatment of embryos with Vitamin C, a prominent antioxidant ([@bib3]), attenuated the severe malformations of Neil2 morphants ([Figure 3G](#fig3){ref-type="fig"}), supporting ROS as the basis of cNCC defects in the absence of Neil2.

A neuroectoderm-restricted Tp53 response triggers neural crest defects in *Xenopus* embryos {#s2-4}
-------------------------------------------------------------------------------------------

The Tp53 response to DNA damage is a widespread cellular phenomenon ([@bib21]). Hence, what restricts the DDR mostly to neuroectoderm during *Xenopus* development? Among the most upregulated genes in Neil2 morphants was the direct Tp53 target gene *cyclin-G1* (*ccng1*) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) ([@bib72]). Ccng1 interacts with Mdm2, another Tp53 target gene, and is involved in a negative feedback loop regulating Tp53 protein levels induced by DNA damage ([@bib53]; [@bib71]). Unilateral injection of *neil2* MO in *Xenopus* embryos with the lineage tracer β-galactosidase confirmed upregulation of *ccng1* on the injected side ([Figure 4A](#fig4){ref-type="fig"}). *Ccng1* induction was restricted to the neural plate even in embryos where the lineage tracer extended to mesoderm and endoderm ([Figure 4A](#fig4){ref-type="fig"}). To test if the spatial restriction of *ccng1* expression reflects tissue-specificity of the DDR, we provoked a systemic DDR using pyocyanin, which induced strong *ccng1* expression ([Figure 4B](#fig4){ref-type="fig"}). As observed in Neil2 morphants, *ccng1* expression was spatially restricted to the neural plate. Spatial restriction of the DDR may be related to patterned expression of *tp53* itself, as in situ hybridization showed preferential *tp53* expression in the neural plate, notably in the anterior wherefrom cNCCs arise ([Figure 4C](#fig4){ref-type="fig"}). High-level expression of *tp53* in the embryonic CNS is observed in diverse vertebrates, including zebrafish, *Xenopus*, chick, and mouse ([@bib44]; [@bib60]; [@bib81]).

![A neuroectoderm-restricted Tp53 DNA damage response triggers neural crest defects in *Xenopus* embryos.\
(**A--D**) Whole mount in situ hybridization for the indicated marker genes in stage 18 *Xenopus* embryos shown in dorsal view or as indicated. Scale bars, 200 µm. (**A**) Embryos were injected unilaterally with control or *neil2* MO (lineage-traced by co-injected *lacZ* mRNA, light blue speckles). (**B**) Embryos were treated with 25 µM pyocyanin or DMSO (solvent). (**C**) Expression of *tp53* in untreated embryos. (**D**) Left, embryos were unilaterally injected with control or *tp53* mRNA (lineage-traced by co-injected *lacZ* mRNA, light blue speckles). Note reduced *snail2* expression in neural crest cells after *tp53* mRNA injection (red arrow). Right, quantification of reduced *snail2* expression (n = 24 and 20 embryos per group, from left to right). (**E**) Left, phenotype of stage 32 embryos injected with control or *tp53* mRNA. Right, quantification of embryo malformations (n = 23 and 19 embryos per group, from left to right). Scale bars, 500 µm. (**F**) qPCR expression analysis of *ccng1* and *eda2r* in embryos at stage 14 injected with MOs as indicated. Expression of *ccng1* and *eda2r* was normalized to *h4* expression and is presented relative to control MO-injected embryos. (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (**G**) Left, phenotypes of stage 32 embryos injected with the indicated MOs. Scale bars, 500 µm. Right, quantification of embryo malformations (n = 25, 26, 19 and 28 embryos per group, from left to right). (**H**) Model for Neil2 function in *Xenopus* neural crest specification. During neural crest development ROS levels are increased and DNA is oxidatively damaged. Unrepaired DNA damage in the absence of Neil2 induces Tp53-DDR followed by intrinsic apoptosis and malformation of neural crest derivatives in the developing embryo. ROS, reactive oxygen species.](elife-49044-fig4){#fig4}

The results suggest that the cNCC defects in Neil2 morphants reflect a neural plate-restricted Tp53-response to oxidative DNA damage. Consistently, *tp53* mRNA injection downregulated the cNCC marker *snail2* at mid neurula stage ([Figure 4D](#fig4){ref-type="fig"}) and induced head and tail abnormalities ([Figure 4E](#fig4){ref-type="fig"}). Importantly, injection of a *tp53* antisense MO ([@bib100]) not only blocked induction of Tp53 target genes in Neil2 morphants but also rescued phenotypic abnormalities substantially ([Figure 4F--G](#fig4){ref-type="fig"}). In sum, we propose that Neil2 protects against an oxidative DNA damage-induced Tp53 response and intrinsic apoptosis in the neural plate, thereby safeguarding cNCC development ([Figure 4H](#fig4){ref-type="fig"}).

Apex1-deficiency phenocopies neural crest defects of Neil2 morphant *Xenopus* embryos {#s2-5}
-------------------------------------------------------------------------------------

We asked if other BER factors have roles similar to Neil2 in *Xenopus* embryogenesis. APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1) functions downstream of DNA glycosylases, processing the abasic (apurinic/apyrimidinic (AP)) sites produced during BER ([@bib1]), and *Apex1*-deficiency in mice leads to early embryonic lethality ([@bib114]). Injection of *apex1* MO at similar dosage as *neil2* MO induced severe abnormalities and early lethality confirming essentiality of Apex1 also for *Xenopus* embryonic development (data not shown). Interestingly, injection of reduced amounts of *apex1* MO phenocopied Neil2 morphants, with embryos displaying microcephaly, and reduced or absent dorsal and tail fins ([Figure 5A](#fig5){ref-type="fig"}). Human *APEX1* mRNA partially rescued the phenotype confirming specificity of the *apex1* MO ([Figure 5A](#fig5){ref-type="fig"}). While Tp53 and phospho-Chk1 levels were unaltered ([Figure 5B](#fig5){ref-type="fig"}), Tp53 target genes were induced in Apex1 morphants ([Figure 5C](#fig5){ref-type="fig"}). As in Neil2 morphants, phospho-histone H3 levels were unchanged and Caspase-3 cleavage was induced ([Figure 5D--E](#fig5){ref-type="fig"}). Hence, the BER enzymes Neil2 and Apex1 exhibit similar functions in *Xenopus* neural crest development.

![*Apex1*-deficiency phenocopies neural crest defects of *Neil2*-morphant *Xenopus* embryos.\
(**A**) Left, phenotypes of stage 39 embryos injected with control and *apex1* MO, and control and human *APEX1* mRNA for phenotypic rescue. Scale bars, 500 µm. Right, quantification of embryo malformation in all four injection groups (n = 34, 23, 29 and 34 embryos per group, from left to right). (**B**) Western blot for total Tp53 and phosphoserine (pS345) Chk1 in stage 14 control and *apex1* MO-injected embryos. Alpha (a-) Tubulin served as loading control. Molecular weight of marker proteins \[x10^−3^\] is indicated on the left. (**C**) qPCR expression analysis of Tp53 target genes in control and *apex1* MO-injected embryos at stage 14. Expression of target genes was normalized to *h4* and is presented as relative mRNA level of control MO-injected embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (**D**) Western blot for phosphoserine (pS10) histone H3 from control and *apex1* MO-injected stage 14 embryos. Alpha (a-) Tubulin served as loading control. (**E**) Western blot analysis for Caspase-3 in control and *apex1* MO-injected stage 14 embryos. Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows).](elife-49044-fig5){#fig5}

*Neil1,2,3* triple-mutant teratomas display cNCC differentiation defects {#s2-6}
------------------------------------------------------------------------

We next investigated if the role of NEIL DNA glycosylases to protect against ROS damage and safeguard neural crest development is conserved in mammals, and used mouse embryonic stem cells (mESCs) as a model system. We generated *Neil1,2,3* triple-knockout (TKO) mESCs by CRISPR/Cas9 genome editing ([@bib22]). We included NEIL3 in addition to NEIL1 and NEIL2 to account for any possible functional redundancy among the NEIL family. The biochemical and biological properties of NEIL3, however, are quite distinct from those of NEIL1 and NEIL2 ([@bib57]; [@bib63]). We flanked and deleted the coding region of the catalytic domains with two gRNAs for each *Neil* gene ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), as validated by genotyping PCR ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Gene inactivation was further confirmed by western blot analysis for NEIL1 and RT-qPCR for *Neil2* and *Neil3* ([Figure 6---figure supplement 1C-D](#fig6s1){ref-type="fig"}). Expression of pluripotency markers was unaltered for *Pou5f1* and *Klf4*, whereas *Nanog* expression was slightly reduced in *Neil1,2,3* TKO mESCs compared to control cells that originated from mock transfections lacking specific guide RNAs ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}).

We subjected control and *Neil*-TKO mESCs to teratoma assays ([@bib79]) using three independent clones of each, to average-out clonal variation. When transplanted subcutaneously into immunodeficient mice, teratomas grew from all six mESC lines. Histological analysis of control and *Neil*-TKO teratomas revealed derivatives of ectoderm, endoderm and mesoderm in all samples confirming pluripotency of *Neil*-deficient mESCs ([Figure 6A](#fig6){ref-type="fig"}). However, transcriptome analysis by RNA-seq uncovered thousands of genes differentially expressed between control and *Neil*-TKO teratomas ([Figure 6B](#fig6){ref-type="fig"}). Intriguingly, pathway enrichment analysis of \>2 fold differentially expressed genes yielded one significant hit for the up- and downregulated genes each, 'PluriNetWork' and 'neural crest differentiation', respectively ([Figure 6C](#fig6){ref-type="fig"}). The term 'PluriNetWork' refers to the genes regulating pluripotency in mouse stem cells ([@bib92]). We confirmed upregulation of pluripotency markers (*Pou5f1, Nanog and Klf4)*, suggesting incomplete silencing of the pluripotent state in *Neil-*TKO teratomas ([Figure 6D](#fig6){ref-type="fig"}). Downregulated genes included neural crest effectors such as *Pax3* ([@bib58]), *Tfap2b, Phox2b, Dbh, Crabp1, Neurog1* and *Wnt3a*, besides a suite of downregulated *Hox* genes (*Hoxa2, Hoxa3, Hoxa4, Hoxa5, Hoxa9, Hoxb1, Hoxb2, Hoxb3, Hoxb4, Hoxb5, Hoxc4, Hoxc5, Hoxd3*), which are prominently expressed during neural crest/pharyngeal arch patterning, where they control head skeletal development ([@bib102]) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). In fact, marker gene analysis for endoderm (*Gata6*), mesoderm (*Eomes*), neuroectoderm (*Pax6, Nestin, Sox1 and Pax2*), and neural crest (*Pax3, Hoxa2, Tfap2b and Neurog1)* indicated mild neural and severe neural crest differentiation defects ([Figure 6E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Moreover, the TP53 target genes *Ccng1, Mdm2, Sesn2* and *Eda2r* were significantly upregulated in *Neil* TKO teratomas ([Figure 6F](#fig6){ref-type="fig"}) indicative of a TP53 DDR. These results indicate that the requirement for NEIL function in cNCC development is evolutionarily conserved between amphibians and mammals.

![*Neil1,2,3*-deficient mESCs display neural crest cell differentiation defects.\
(**A**) Histological analysis of H and E stained teratomas derived from control and *Neil1,2,3*-deficient mESC lines. Arrows indicate neural tube- (ectoderm), gut epithelium- (endoderm) and cartilage- (mesoderm) related structures within each section. (**B**) Quantification of differentially expressed genes in *Neil1,2,3*-deficient teratomas. (**C**) Pathway enrichment analysis of up- and downregulated genes in *Neil1,2,3*-deficient teratomas. Dashed line indicates the significance threshold FDR = 0.05. (**D**) qPCR expression analysis of pluripotency genes in control and *Neil1,2,3* triple-deficient teratomas. Marker gene expression was normalized to *Tbp* and is presented relative to control teraomas (mean ±s.d., n = 3 biological replicates with each three technical replicates). (**E**) qPCR expression analysis as in (**D**) but of endoderm (*Gata6*), mesoderm (*Eomes*), neuroectoderm (*Pax6*) and neural crest (*Pax3*) marker genes of control and *Neil1,2,3*-deficient teratomas. (**F**) qPCR expression analysis as in (**D**) but of selected TP53 target genes.](elife-49044-fig6){#fig6}

Neural and cNCC differentiation defects are caused by *Neil1*- and *Neil2*-deficiency {#s2-7}
-------------------------------------------------------------------------------------

To analyze the individual requirement of NEILs for neural and cNCC specification, we generated single *Neil1, −2, and −3* mutant mESCs ([Figure 7---figure supplement 1A--D](#fig7s1){ref-type="fig"}). *Neil*-mutant mESCs were subjected to in vitro differentiation for eight days in embryoid bodies (EB) in absence or presence of retinoic acid (RA), the latter favoring neural differentiation ([@bib9]). *Neil3* mutants were largely unaffected for all markers tested ([Figure 7A](#fig7){ref-type="fig"}). In contrast, single *Neil1* and *Neil2* mutants showed significant reduction in neural crest marker (*Pax3, Hoxa2, Tfapb2, Neurog1*) and also pan-neuroectodermal marker (*Pax6, Nestin, Sox1, Pax2*) expression, while endoderm- and mesoderm markers were unaffected ([Figure 7A](#fig7){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Importantly, *Pax3* and *Pax6* induction during differentiation was partially restored in *Neil1*- and *Neil2*-deficient cells by stable transfection with catalytically active- but not inactive human NEIL1- and NEIL2*-*encoding constructs ([Figure 7---figure supplement 3A](#fig7s3){ref-type="fig"}). Note that the degree of rescue was likely limited by the low expression of the transfected NEIL constructs ([Figure 7---figure supplement 3B](#fig7s3){ref-type="fig"}). This rescue not only confirms specificity of the *Neil* knockout approach but also demonstrates that the neural and cNCC differentiation defects are not due to mutant mESCs having undergone irreversible changes/DNA damage. Instead, the rescue indicates an acute requirement for NEIL1 and NEIL2 during cNCC differentiation.

![*Neil1-* and *Neil2*-deficient mESCs display neural crest cell differentiation defects in vitro.\
(**A**) qPCR expression analysis of pluripotency (*Pou5f1*), endoderm (*Gata6*), mesoderm (*Eomes*), neuroectoderm (*Pax6*) and neural crest (*Pax3*) marker genes of the indicated *Neil*-mutant mESCs. Cells were differentiated into embryoid bodies (EBs) without or with retinoic acid (EBs + RA). Expression of marker genes was normalized to *Tbp* and is relative to control clones in mESC state. (s.d., n = 3 biological replicates). (**B**) Quantification of differentially expressed genes in *Neil1* and *Neil2* single-deficient mESCs, EBs and EBs + RA. (**C**) Overlap of differentially expressed genes from *Neil1* and *Neil2* single-deficient EBs (left panel) and EBs + RA (right panel) (**D**) Pathway enrichment analysis of downregulated genes from *Neil1* (upper) and *Neil2* (lower panel) single-deficient EBs + RA. Dashed lines indicate the significance threshold FDR = 0.05. (**E**) Overlap of downregulated genes from *Neil1* and *Neil2* single-deficient EBs + RA, and downregulated genes from *Neil1,2,3-*deficient teratomas.](elife-49044-fig7){#fig7}

To corroborate neural and cNCC developmental defects, we carried out RNA-seq analysis of undifferentiated- and embryoid-body differentiated *Neil1* and *Neil2* single-mutant mESCs. While we observed hundreds of differentially expressed (DE) genes in mutant *Neil1* and *Neil2* mESCs ([Figure 7B](#fig7){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}--[4](#supp4){ref-type="supplementary-material"}), they did not cluster when subjected to pathway enrichment analysis. Upon differentiation, the number of DE genes increased in *Neil1*- and *Neil2-*deficient cells substantially to several thousand, notably in EBs treated with RA, with up- and downregulated genes equally distributed ([Figure 7B](#fig7){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}--[4](#supp4){ref-type="supplementary-material"}). The majority of DE genes overlapped between *Neil1* and *−2* mutant EBs and EBs + RA ([Figure 7C](#fig7){ref-type="fig"}), supporting functional commonality between NEIL1 and NEIL2. Importantly, pathway enrichment analysis of the downregulated genes revealed 'neural crest differentiation' as the top hit in both genotypes and in both differentiation regimes ([Figure 7D](#fig7){ref-type="fig"} and [Figure 7---figure supplement 4A](#fig7s4){ref-type="fig"}). Downregulated genes included the neural crest effectors *Pax3, Tfap2b, Phox2b, Crabp1, Neurog1* and a series of *Hox* genes ([Supplementary file 3](#supp3){ref-type="supplementary-material"}--[4](#supp4){ref-type="supplementary-material"}) similarly as for *Neil*-TKO teratomas. Downregulated genes from *Neil-*TKO teratomas significantly overlapped with downregulated genes from either *Neil1-* or *Neil2*-mutant EBs and EBs + RA ([Figure 7---figure supplement 4B](#fig7s4){ref-type="fig"} and [Figure 7E](#fig7){ref-type="fig"}). We conclude that in vitro differentiation of *Neil1-* and *Neil2* single-mutant mESCs recapitulates neural and cNCC differentiation defects observed in *Neil*-TKO teratomas. Besides, the upregulated genes of both *Neil1-* and *Neil2-*deficient EBs + RA were significantly enriched for the pathway term 'TYROBP causal network' ([Figure 7---figure supplement 4C](#fig7s4){ref-type="fig"}), associated with late-onset Alzheimer's disease ([@bib116]).

*Apex1*-deficiency phenocopies neural and cNCC differentiation defects of *Neil1* and *Neil2* mutants {#s2-8}
-----------------------------------------------------------------------------------------------------

We asked if *Apex1*-deficiency in mESC differentiation phenocopies *Neil*-deficiency as observed in *Xenopus* embryos. Hence, we generated and validated an *Apex1* mESC knockout-line (*Apex1* \#46, [Figure 8---figure supplement 1A--D](#fig8s1){ref-type="fig"}) and subjected it to in vitro differentiation. Expression of germ layer marker genes was reduced for all tested tissues in the *Apex1*-mutant line ([Figure 8A](#fig8){ref-type="fig"}), indicating a more severe differentiation defect than in *Neil1* and *Neil2* mutants. Yet, RNA-seq analysis revealed a substantial overlap of commonly deregulated genes between *Neil1*-, *Neil2*- and *Apex1*-deficient EBs treated with RA ([Figure 8B--C](#fig8){ref-type="fig"} and [Supplementary file 5](#supp5){ref-type="supplementary-material"}). Moreover, pathway enrichment analysis of the downregulated genes in *Apex1* EBs + RA once again resulted in 'neural crest development' as the top hit ([Figure 8D](#fig8){ref-type="fig"}). Thus, *Apex1*-deficient mESCs substantially phenocopy cNCC differentiation defects of *Neil* mutants similar to *Xenopus* embryos.

![*Apex1*-deficiency leads to neural crest cell differentiation defects.\
(**A**) qPCR expression analysis of pluripotency (*Pou5f1*), endoderm (*Gata6*), mesoderm (*Eomes*), neuroectoderm (*Pax6*) and neural crest (*Pax3*) marker genes of control and *Apex1*-deficient mESCs, EBs and EBs + RA. Expression of marker genes was normalized to *Tbp* and is relative to control mESCs (s.d., n = 3 technical replicates). (**B**) Quantification of differentially expressed genes in *Apex1*-deficient mESCs, EBs and EBs + RA. (**C**) Overlap of differentially expressed genes from *Neil1*, *Neil2 and Apex1* single-deficient EBs + RA. (**D**) Pathway enrichment analysis of downregulated genes from *Apex1*-deficient EBs + RA. Dashed line indicates the significance threshold FDR = 0.05.](elife-49044-fig8){#fig8}

Neural and cNCC differentiation in embryoid bodies is independent of oxidative DNA demethylation {#s2-9}
------------------------------------------------------------------------------------------------

We tested if active removal of the oxidative demethylation intermediates 5fC and 5caC is required for neural and cNCC differentiation in EBs. To this end, we generated a *Tdg* mESC knockout-line using CRISPR/Cas9 (*Tdg* \#25, [Figure 9---figure supplement 1A--C](#fig9s1){ref-type="fig"}). *Tdg* knockout mice are embryonic lethal and *Tdg*-deficient mESCs fail to undergo terminal neuronal differentiation ([@bib23]). As expected, *Tdg*-deficient mESCs had 3--4-fold increased genomic 5fC and 5caC levels ([@bib88]; [@bib95]), but they showed no change in pluripotency marker expression ([Figure 9---figure supplement 1D--E](#fig9s1){ref-type="fig"}). Moreover, *Tdg*-deficient cells subjected to EB differentiation induced marker gene expression of all germ layers with no significant difference from control cells ([Figure 9A](#fig9){ref-type="fig"}). We conclude that oxidative *Tdg*-dependent DNA demethylation is not required for early cNCC differentiation in embryoid bodies.

![Neural differentiation is independent of the role of NEIL DNA glycosylases in oxidative DNA demethylation.\
(**A**) qPCR expression analysis of pluripotency (*Pou5f1*), endoderm (*Gata6*), mesoderm (*Eomes*), neuroectoderm (*Pax6*) and neural crest (*Pax3*) marker genes of control and *Tdg*-deficient mESCs, EBs, and EBs + RA. Expression of marker genes was normalized to *Tbp* and is relative to control mESCs (s.d., n = 3 technical replicates). (**B**) qPCR expression analysis as in (**A**) but of control, *Neil1* and *Tdg* single- and double-deficient mESCs, EBs and EBs + RA. Expression of marker genes was normalized to *Tbp* and is relative to double-control clone in mESC state (s.d., n = 3 technical replicates).](elife-49044-fig9){#fig9}

NEIL1 and NEIL2 are involved in handover and processing of abasic sites during oxidative DNA demethylation after 5fC/5caC excision by TDG ([@bib86]). Since abasic sites are genotoxic, *Neil*-deficiency may trigger a DDR because of accumulation of unprocessed TET/TDG-demethylation intermediates. If so, preventing 5fC/5caC excision in the first place should rescue the differentiation defects in *Neil*-deficient cells. To block 5fC/5caC excision, we generated a *Tdg*-knockout mESC line in a *Neil1*-deficient background (*Neil1* \#7/*Tdg* \#11, [Figure 9---figure supplement 2A--E](#fig9s2){ref-type="fig"}). However, in the *Neil1*/*Tdg* double-knockout line there was no rescue of cNCC differentiation, while the *Tdg*-single mutant line expectedly showed normal neural and cNCC marker gene expression ([Figure 9B](#fig9){ref-type="fig"}). We conclude that the differentiation defects induced by deficiency of *Neils* are independent of a role in oxidative DNA demethylation.

Mitochondrial oxidative DNA damage is increased in *Neil1*- and *Neil2*-deficient cells during neural differentiation {#s2-10}
---------------------------------------------------------------------------------------------------------------------

To test if defective neural and cNCC differentiation is related to elevated oxidative DNA damage as in *Xenopus*, we differentiated mESCs in the presence of pyocyanin. Consistently, pyocyanin inhibited neural and cNCC gene expression upon RA-induced EB differentiation, without affecting endoderm or mesoderm differentiation ([Figure 10A](#fig10){ref-type="fig"}). In addition, upon differentiation, TP53 target gene expression significantly increased in presence of pyocyanin compared to mock treatment ([Figure 10B](#fig10){ref-type="fig"}). The results align with the observation that oxidative stress impairs cNCC differentiation ([@bib19]; [@bib85]; [@bib115]).

![Oxidative stress impairs cNCC differentiation in mESCs.\
(**A**) qPCR expression analysis of pluripotency (*Pou5f1*), endoderm (*Gata6*), mesoderm (*Eomes*), neuroectoderm (*Pax6*) and neural crest (*Pax3*) marker genes of mock and pyocyanin-treated control mESCs, EBs and EBs + RA. Expression of marker genes was normalized to *Tbp* and is relative to mock-treated mESCs (s.d., n = 3 technical replicates). (**B**) qPCR expression analysis as in (**A**) but of selected TP53 target genes of mock (DMSO) and pyocyanin-treated control mESCs, EBs and EBs + RA.](elife-49044-fig10){#fig10}

Hence, the *Xenopus* and mESC data converge on the conclusion that NEIL1 and NEIL2 are required to repair oxidative base lesions during early neural development. Since NEIL1 and NEIL2 localize to- and maintain genomic stability in the nucleus as well as in mitochondria ([@bib45]; [@bib68]; [@bib75]; [@bib105]), this raised the question, in which of these two compartments NEILs may be required during early embryogenesis. To quantify NEIL-processed lesions, we developed a novel protocol. We isolated gDNA and mtDNA (\>14 fold enriched for mtDNA, [Figure 11---figure supplement 1A](#fig11s1){ref-type="fig"}), and digested it with *E. coli* EndoIII, a bifunctional DNA glycosylase/AP lyase that excises a similar spectrum of oxidatively damaged DNA bases as NEIL1 and NEIL2 ([@bib25]). EndoIII base excision at oxidative lesions generates abasic sites ([@bib35]), which are then quantified by LC-MS/MS mass spectrometry ([@bib78]). Since steady state levels of endogenous abasic sites in DNA are more abundant than oxidative base damages ([@bib97]) we pretreated the DNA with recombinant APEX1 prior to the EndoIII reaction in order to reduce the background from preexisting abasic sites ([Figure 11A](#fig11){ref-type="fig"} and [Figure 11---figure supplement 1B](#fig11s1){ref-type="fig"}). Quantification of abasic sites on synthetic oligonucleotides mixed with known amounts of AP sites accurately matched the expected result ([Figure 11---figure supplement 1C](#fig11s1){ref-type="fig"}), validating the method. We noted, though, that APEX1-treatment did not completely erase abasic sites on oligonucleotides under our reaction conditions. Similarly, EndoIII processed the oxidative damage 5hU on oligonucleotides to abasic sites, but also not completely ([Figure 11---figure supplement 1C](#fig11s1){ref-type="fig"}).

![Oxidative mtDNA damage and mitochondrial dysfunction in *Neil1*- and *Neil2*-deficient embryoid bodies.\
(**A**) Workflow to quantify oxidative base lesions in DNA. Isolated genomic and mtDNA is consecutively treated with recombinant APEX1 and EndoIII to monitor endogenous EndoIII-processed oxidative base damages by LC-MS/MS. (**B**) LC-MS/MS quantification of base lesions as described in (**A**) using gDNA and mtDNA of control, *Neil1*- and *Neil2*-deficient mESCs, EBs and EBs + RA as indicated (s.d., n = 3 biological replicates). Abasic site levels are presented in percent of total amount of nucleotides (**N**). (**C**) Left, position of the mitochondrial (mt-) genomic fragments tested for DNA damage (1-3) relative to the nucleotide annotation of the mt genome (inner circle numbers in kb). Right, mtDNA damage in mt-fragments 1--3 in *Neil1*- and *Neil2*-deficient mESCs, EBs and EBs + RA, respectively, calculated as lesions over control in 10 kb (s.d., n = 3 biological replicates). Note, a negative value corresponds to less damage in *Neil*-deficient compared to control cells. (**D**) qPCR expression analysis of genes for oxidative phosphorylation (OXPHOS) encoded either on mitochondrial (mt-) or nuclear (n-) DNA in control, *Neil1* and *Neil2* single-mutant mESCs, EBs and EBs + RA. Expression of marker genes was normalized to *Tbp* and is relative to control mESCs (s.d., n = 3 biological replicates).](elife-49044-fig11){#fig11}

APEX1-treatment of purified gDNA from mESCs reduced endogenous abasic sites by two-fold, from \~229.000 sites per genome to \~120.000 sites per genome. Subsequent EndoIII incubation led to a statistically significant increase of \~29.000 abasic sites per genome ([Figure 11---figure supplement 1D](#fig11s1){ref-type="fig"}). Thus, steady state levels of EndoIII-reactive DNA damage sites were \~8 fold lower than the level of abasic sites, in agreement with previous reports ([@bib97]). Levels of endogenous abasic sites (without APEX1/EndoIII treatment) were unaffected by *Neil1-* and *Neil2*-deficiency in gDNA and mtDNA, regardless of whether mESCs were differentiated or not ([Figure 11---figure supplement 1E](#fig11s1){ref-type="fig"}). Likewise, there was no significant increase in EndoIII-processed sites in gDNA from *Neil1-* and *Neil2*-knockout cells ([Figure 11B](#fig11){ref-type="fig"}, top). In contrast, in mtDNA from *Neil1-* and *Neil2*-deficient mESCs, EndoIII-created abasic sites were elevated only upon neural differentiation (EB + RA), but not in EBs or undifferentiated mESCs ([Figure 11B](#fig11){ref-type="fig"}, bottom).

We confirmed elevated mtDNA damage in *Neil1-* and *Neil2*-deficient EBs + RA by an independent method ([@bib33]). Using long-range PCR, levels of DNA damage are monitored based on the fact that DNA lesions inhibit DNA polymerase and slow down accumulation of the PCR product. Therefore, the rate of product amplification is inversely proportional to the number of damaged DNA molecules. Comparing *Neil*-deficient to control cells, this approach revealed increased mtDNA damage in EBs treated with RA, and to lesser extend in EBs without RA ([Figure 11C](#fig11){ref-type="fig"}).

Moreover, as in *Xenopus* embryos we detected significant upregulation of mitochondrial and nuclear genes encoding components of oxidative phosphorylation as sign of mitochondrial dysfunction in *Neil1*- and *Neil2*-knockout cells, specifically under EB + RA treatment ([Figure 11D](#fig11){ref-type="fig"}) ([@bib4]; [@bib39]; [@bib80]). Together, the results suggest that NEIL1 and NEIL2 are specifically required for processing of oxidative lesions occurring in mitochondrial DNA during neural differentiation.

Mitochondrial TP53 DDR causes neural and cNCC differentiation defects upon *Neil1*- and *Neil2*-deficiency {#s2-11}
----------------------------------------------------------------------------------------------------------

We asked if *Neil*-deficiency in mESCs elicits a DNA damage response as in *Xenopus* embryos. Indeed, we found a \~ 40% overlap between the 116 top TP53 target genes ([@bib29]) and the upregulated genes in *Neil1-* and *Neil2*-mutant EBs + RA ([Figure 12A](#fig12){ref-type="fig"}), but no significant overlap with *Neil1-* and *Neil2*-deficient EBs and mESCs ([Figure 12---figure supplement 1A--B](#fig12s1){ref-type="fig"}). Furthermore, differentiation of control mESCs in presence of the TP53 stabilizer NSC 146109 ([@bib8]) resulted in specific neural and cNCC differentiation defects, thus mimicking *Neil*-deficiency ([Figure 12B](#fig12){ref-type="fig"}). Moreover, we tested if TP53 inhibition could rescue impaired differentiation of *Neil1-* and *Neil2-*mutant mESCs. We differentiated *Neil1* and *Neil2* single mutant mESCs in the presence of Pifithrin-α, an inhibitor of TP53 ([@bib55]). Strikingly, upon Pifithrin-α treatment the neuronal marker *Pax6* and neural crest marker *Pax3* in *Neil1-* and *Neil2*-mutant EBs + RA regained expression levels of control cells, while endoderm and mesoderm differentiation was marginally inhibited in all tested genotypes ([Figure 12C](#fig12){ref-type="fig"}). In control EBs + RA Pifithrin-α treatment did not affect *Pax6* and *Pax3* expression. We conclude that an upregulated TP53 DDR impairs neural and cNCC differentiation in *Neil1-* and *Neil2*-mutant cells.

![*Neil*-deficiency induces a TP53-mediated intrinsic apoptosis in embryoid bodies.\
(**A**) Overlap of upregulated genes from *Neil1* and *Neil2* single-deficient EBs + RA, and 116 direct TP53 target genes ([@bib29]). (**B**) qPCR expression analysis of the indicated marker genes in mock (DMSO) and NSC 146109- (TP53 stabilizer) treated control mESCs, EBs and EBs + RA. Expression of marker genes was normalized to *Tbp* and is relative to mock-treated mESCs (s.d., n = 3 technical replicates). (**C**) qPCR expression analysis of marker genes as in (**B**) in control, *Neil1* and *Neil2* single-mutant mESCs, EBs and EBs + RA treated with 50 µM Pifithrin-α or mock treated (DMSO). Expression of marker genes was normalized to *Tbp* and is relative to mock-treated control mESCs (s.d., n = 3 biological replicates). (**D**) qPCR expression analysis of *Bcl-2* and *Bak-1* in *Neil1* and *Neil2* single-deficient mESCs, EBs and EBs + RA. Expression of both genes was normalized to *Tbp* and is relative to control mESC clones (s.d., n = 3 biological replicates). (**E**) Model for the role of NEIL1 and NEIL2 in mESC differentiation towards cNCC/neural cells. Neurogenesis is accompanied by a metabolic switch from glycolysis to oxidative phosphorylation, a concomitant increase in mass and number of mitochondria per cell and hence escalated oxidative stress. High ROS levels render neural and neural crest cells particularly vulnerable to oxidative DNA damage and thus dependent on efficient damage repair, including by NEIL1 and NEIL2. Upon NEIL-deficiency, oxidative mtDNA damage induces apoptosis impairing neural and neural crest differentiation. ROS, reactive oxygen species.](elife-49044-fig12){#fig12}

Since we observed mtDNA damage accumulation and mitochondrial dysfunction in *Neil1-* and *Neil2*-deficient cells, we tested specifically for a mitochondrial TP53 DDR ([@bib106]) as in *Xenopus*. Expression of the anti-apoptotic factor *Bcl2* was strongly downregulated in *Neil*-mutant EBs and EBs + RA, while expression of *Bak1*, a pro-apoptotic factor of the *Bcl2* family ([@bib32]; [@bib103]), was significantly induced in *Neil*-deficient EBs + RA ([Figure 12D](#fig12){ref-type="fig"}), consistent with an intrinsic/mitochondrial TP53 response. Pifithrin-α treatment reversed repression of *Bcl2* and induction of *Bak1* in *Neil*-deficient EBs + RA, confirming a TP53-dependent regulation of both genes ([Figure 12---figure supplement 1C](#fig12s1){ref-type="fig"}).

The apoptosis effector CASPASE-3 is induced upon- and required for mESC neural differentiation ([@bib30]). Concordantly, levels of CASPASE-3 (cleaved and uncleaved) were systematically decreased in *Neil*-deficient EBs + RA ([Figure 12---figure supplement 2A](#fig12s2){ref-type="fig"}), thus different from Caspase-3-effected apoptosis in *Xenopus* ([Figure 1I](#fig1){ref-type="fig"}). Levels of CASPASE-7, the alternative effector caspase of the intrinsic apoptosis pathway ([@bib59]), were unchanged ([Figure 12---figure supplement 2B](#fig12s2){ref-type="fig"}).

Among the upregulated TP53-target genes in *Neil*-deficient EBs + RA were effectors of cell cycle arrest (e.g. *Cdkn1a*). We therefore tested for cell cycle differences in *Neil1-* and *Neil2*-deficient cells by flow cytometry analysis. However, while cell cycle profiles of EBs and EBs + RA were clearly distinguishable from mESCs (more G1-phase and fewer S- and G2/M-phase cells upon mESC differentiation; [@bib110]), there were no significant differences in cell cycle profiles between the control and *Neil1-* or *Neil2*-deficient cells, arguing against a TP53-induced cell cycle arrest ([Figure 12---figure supplement 2C](#fig12s2){ref-type="fig"}). In line, cell cycle effects are also absent after forced TP53 induction in neural crest cells in mice ([@bib11]).

Collectively, the results support a model in which NEIL1 and NEIL2 function as mitochondrial DNA repair glycosylases to counteract an increased oxidative stress during neurogenesis. Thereby, NEIL1 and NEIL2 protect against a mitochondrial-induced TP53-DDR and an intrinsic apoptosis pathway, and safeguard neural differentiation ([Figure 12E](#fig12){ref-type="fig"}).

Discussion {#s3}
==========

One-third of all congenital birth defects are craniofacial malformations that arise by perturbations in cNCC development ([@bib85]). Hence, understanding the environmental and genetic causes leading to perturbations of cNCC development is important for the development of potential therapeutic avenues for their prevention. The main finding of our study is the elucidation of a mechanism whereby disruption of the ubiquitous DNA glycosylases NEIL1 and NEIL2 leads to neural and cNCC differentiation defects during embryonic development. Our study indicates that cNCC defects caused by NEIL1- and NEIL2-deficiency are attributable primarily to their role in protecting against oxidative DNA lesions, in particular of the mitochondrial genome, rather than in promoting epigenetic DNA demethylation. Our study, therefore, links mitochondrial BER to neural cell differentiation.

The physiological role of NEIL1 and NEIL2 DNA glycosylases has previously been analyzed in mouse mutants. *Neil1* mutants present metabolic syndrome and show impaired brain function and neuronal stress resistance in adults ([@bib14]; [@bib15]; [@bib105]). *Neil2*-null mice are susceptible to innate inflammation ([@bib16]). These abnormalities were accompanied by BER defects in both types of mutants. *Neil1,2,3* triple-mutant mice were recently reported to be viable, but mice were only analyzed- and reported negative for cancer predisposition ([@bib82]).

In contrast, we found that cNCC development showed a surprisingly specific vulnerability towards NEIL-deficiency both in *Xenopus* embryos (Neil2) as well as in differentiating mESCs (NEIL1 and NEIL2). Deficiency of NEIL3, which processes a different spectrum of lesions compared to NEIL1 and NEIL2 and is not found in mitochondria ([@bib75]), had no effect on neural and cNCC development. The cNCC abnormalities in *Xenopus* were mirrored in the transcriptome of differentiating *Neil1-* and *Neil2*-deficient mESCs. In *Xenopus* embryos and mESCs, we elucidated the mechanism as a TP53-mediated DNA damage response, which induced apoptosis in *Xenopus* (Caspase-3-dependent) and mouse EBs (downregulation of *Bcl2* and induction of *Bak1*) without major effects on the cell cycle in both model systems. Moreover, in *Xenopus* and mESCs we found that elevated ROS reduced cNCC specification, supporting a conserved mechanism whereby an oxidative DNA damage response impairs cNCC differentiation.

Similarly, *Apex1* mutant mESCs and Apex1 *Xenopus* morphants displayed cNCC differentiation defects, although gene misregulation (mESCs) and malformations (*Xenopus*) were more severe than in *Neil*-mutant mESCs and Neil2 morphants, consistent with early embryonic lethality of *Apex1* mutant mice ([@bib66]; [@bib114]). In contrast, neither did *Tdg*-deficiency affect cNCC differentiation in mESCs, nor did combined *Tdg/Neil1*-deficiency rescue cNCC differentiation defects, arguing against oxidative DNA demethylation as the primary cause of the differentiation defect.

The question arises, why are neural and neural crest cells particularly sensitive to oxidative DNA damage? Similarly, why is the systemic oxidative stress response to pyocyanin in *Xenopus* embryos limited to neuroectoderm ([Figure 4B](#fig4){ref-type="fig"})? Neurogenesis is accompanied by a metabolic switch from glycolysis to oxidative phosphorylation and, hence, escalated oxidative stress ([@bib52]). High intrinsic ROS levels may render neural crest cells particularly vulnerable to oxidative DNA damage and thus dependent on efficient damage repair. Consistently, neuroectoderm expresses high levels of DNA repair factors ([@bib2]) and of *Tp53* itself ([@bib20]; [@bib43]; [@bib81]); this study), suggesting a specific adaptation to a lesion-prone environment.

Intriguingly, we identified mitochondrial DNA as the primary target for oxidative DNA damage in the absence of NEIL1 and NEIL2 and specifically upon mESC neural differentiation. This suggests a model whereby NEIL1 and NEIL2 function to repair and protect the mitochondrial genome against oxidative damages that accompany the metabolic switch upon neural differentiation. Thereby, NEIL1 and NEIL2 shelter neural specification from an intrinsic, mitochondrial-induced apoptosis pathway ([Figure 12E](#fig12){ref-type="fig"}). NEIL1 and NEIL2 both localize in mitochondria besides the nucleus ([@bib45]; [@bib68]). Moreover, *Neil1*-mutant mice harbor increased mtDNA damage in liver tissue, which might be related to the metabolic syndrome observed in these mice ([@bib105]). Our study therefore corroborates the physiological relevance of NEIL1 and NEIL2 in mtDNA repair and ties mitochondrial BER to cell differentiation. Similarly, the observed neural and cNCC differentiation defects of *Apex1*-mutant cells ([Figure 8](#fig8){ref-type="fig"}) and *Xenopus* Apex1 morphants ([Figure 5](#fig5){ref-type="fig"}) might partly be due to inefficient abasic site repair of mtDNA, as a truncated APEX1 is present in mitochondria ([@bib18]).

Our findings align with studies, which documented a role of TP53 in vertebrate neural crest formation. In chick embryos, TP53 stabilization decreases cNCC differentiation, while dominant-negative TP53 increases the number of cNCC progenitors ([@bib81]). TP53 activation in mouse embryos specifically causes severe neural crest defects ([@bib11]; [@bib104]). Moreover, Treacher Collins syndrome (TCS), a congenital disorder characterized by severe cNCC and craniofacial anomalies, is caused by impaired ribosomal biogenesis due to deficiency in the Pol I transcription machinery, nucleolar dysfunction and/or rDNA damage, resulting in TP53 activation ([@bib13]). Consequently, partial TP53 deficiency or pharmacologic TP53 inhibition ameliorates the craniofacial defects in TCS-mutants ([@bib51]; [@bib84]), emphasizing the role of TP53 in cNCC development. Our results support the observation that neural tissue is particularly vulnerable to *Neil1*-deficiency in adults and is linked to neurodegenerative disease ([@bib14]; [@bib15]; [@bib105]).

Why then do *Neil1-* and *Neil2*-mutant mice develop without obvious neural malformations? First, genetic compensation of *Neil*-mutants may occur via *Nthl1*, which has an overlapping substrate spectrum and also localizes both in the nucleus and mitochondria ([@bib48]; [@bib50]). Single-knockout mice deficient for *Neil1* and *Nthl1* are phenotypically inconspicuous, the combined knockout, however, is highly cancer prone, indicative of mutual compensation of both factors for oxidative DNA damage repair ([@bib17]). mESC differentiation in vitro may not reproduce the complexity of in utero development where transcriptomic fine-tuning can buffer genetic ablations in the developing embryo. Second, differentiating mESCs in vitro experience gas phase oxygen partial pressure (pO~2~) of 142 mmHg, whereas embryonic cells in vivo are exposed to pO~2~ values of 0--30 mmHg ([@bib74]). Similarly, one millimeter-sized *Xenopus* embryos developing close to the air-aquatic interface likely experience pO~2~ levels closer to ambient partial pressure. Hence, cNCCs in differentiating mESCs as well as frog embryos have to cope with higher pO~2~ and hence ROS levels than is the case for mouse embryos in utero. Increased basal ROS levels might sensitize cultured cells and frog embryos when challenged by *Neil*-deficiency during neural and cNCC differentiation. Third, apparently none of the *Neil*-mutant studies has specifically investigated whether *Neil*-deficient mice exhibit cNCC development-related cranial malformations, which may require special bone- and cartilage staining procedures for detection. Hence, our results call for a (re-)analysis of *Neil*-mutant mice for cranial abnormalities possibly under high fat diet, which favors basal ROS production ([@bib107]).

Our findings also support the proposition that antioxidant supplementation may be beneficial for the prevention of craniofacial defects ([@bib84]), since environmental factors such as alcohol and nicotine promote ROS formation ([@bib112]; [@bib118]). We also note that *Neil1* is one of 11 genes affected in a chromosomal micro-deletion of a patient presenting craniofacial defects ([@bib61]).

Finally, while our study demonstrates the importance of NEIL1 and NEIL2 to protect cNCCs against oxidative DNA damage, it does not exclude that NEIL1 and NEIL2 play a physiological role in TET/TDG-mediated gene regulation in other embryonic processes or adult tissues. Elucidating such direct gene-regulatory roles may require genome-wide monitoring of 5mC and its oxidation products in *Neil*-mutants. The here-established *Neil*-, *Apex1-* and *Tdg-*mutant mESCs will be useful for this and other investigations into the biology and mechanisms of BER enzymes.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                  Designation                                                      Source or\                                                       Identifiers                                                                                                                            Additional\
  (species) or\                                                                                                   reference                                                                                                                                                                                               information
  resource                                                                                                                                                                                                                                                                                                                
  ---------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
  Gene (*Homo sapiens*)                          *NEIL1*                                                          ORFeome clone collection                                         BC010876.1                                                                                                                             

  Gene (*Homo sapiens*)                          *NEIL2*                                                          ORFeome clone collection                                         BC013964.2                                                                                                                             

  Gene (*Homo sapiens*)                          *APEX1*                                                          ORFeome clone collection                                         BC008145.1                                                                                                                             

  Gene (*Xenopus tropicalis*)                    *bcl2l1*                                                         Dharmacon                                                        MXT1765-202788918                                                                                                                      

  Strain, strain background (*Xenopus laevis*)   *Xenopus leavis*                                                 Nasco                                                            not available                                                                                                                          

  Cell line (*Mus musculus*)                     E14TG2a                                                          ATCC                                                             CRL-1821                                                                                                                               murine embryonic stem cells

  Cell line (*Mus musculus*)                     E14TG2a clone Control \#1                                        this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Control \#4                                        this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Control \#7                                        this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1,2,3-/- \#23                                  this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1,2,3-/- \#85                                  this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1,2,3-/- \#93                                  this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#7                                       this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#9                                       this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#11                                      this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil2-/- \#1                                       this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil2-/- \#11                                      this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil2-/- \#14                                      this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil3-/- \#3                                       this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil3-/- \#23                                      this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Neil3-/- \#28                                      this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Apex1-/- \#46                                      this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Tdg-/- \#25                                        this paper                                                                                                                                                                                              generated from E14TG2a

  Cell line (*Mus musculus*)                     E14TG2a clone Control \#4 + Control \#1                          this paper                                                                                                                                                                                              generated from E14TG2a clone Control \#4

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#7 + Control \#1                         this paper                                                                                                                                                                                              generated from E14TG2a clone Neil1-/- \#7

  Cell line (*Mus musculus*)                     E14TG2a clone Control \#4 + Tdg-/- \#7                           this paper                                                                                                                                                                                              generated from E14TG2a clone Control \#4

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#7 + Tdg-/- \#11                         this paper                                                                                                                                                                                              generated from E14TG2a clone Neil1-/- \#7

  Cell line (*Mus musculus*)                     E14TG2a clone Control \#4 + pcDNA3.1_empty                       this paper                                                                                                                                                                                              generated from E14TG2a clone Control \#4

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#7 + pcDNA3.1_empty                      this paper                                                                                                                                                                                              generated from E14TG2a clone Neil1-/- \#7

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#7 + pcDNA3.1_NEIL1-2xFLAG (active)      this paper                                                                                                                                                                                              generated from E14TG2a clone Neil1-/- \#7

  Cell line (*Mus musculus*)                     E14TG2a clone Neil1-/- \#7 + pcDNA3.1_2xFLAG-NEIL1 (inactive)    this paper                                                                                                                                                                                              generated from E14TG2a clone Neil1-/- \#7

  Cell line (*Mus musculus*)                     E14TG2a clone Neil2-/- \#11 + pcDNA3.1_empty                     this paper                                                                                                                                                                                              generated from E14TG2a clone Neil2-/- \#11

  Cell line (*Mus musculus*)                     E14TG2a clone Neil2-/- \#11 + pcDNA3.1_NEIL2-2xFLAG (active)     this paper                                                                                                                                                                                              generated from E14TG2a clone Neil2-/- \#11

  Cell line (*Mus musculus*)                     E14TG2a clone Neil2-/- \#11 + pcDNA3.1_2xFLAG-NEIL2 (inactive)   this paper                                                                                                                                                                                              generated from E14TG2a clone Neil2-/- \#11

  Antibody                                       mouse monoclonal anti-alpha tubulin                              Sigma                                                            T5168                                                                                                                                  (1: 1000)

  Antibody                                       rabbit polyclonal anti-NEIL1                                     Abcam                                                            ab21337 (discontinued)                                                                                                                 (1: 500)

  Antibody                                       rabbit polyclonal anti-NEIL2                                     Abcam                                                            ab124106 (discontinued)                                                                                                                (1: 1000)

  Antibody                                       rabbit polyclonal anti-APE1                                      Abcam                                                            ab137708                                                                                                                               (1: 1000)

  Antibody                                       rabbit polyclonal anti-phospho-Chk1 (Ser345)                     Cell Signaling                                                   \#2341                                                                                                                                 (1: 1000)

  Antibody                                       mouse monoclonal anti-p53 (X77)                                  Thermo Fisher Scientific                                         MA1-12549                                                                                                                              (1: 1000)

  Antibody                                       rabbit polyclonal anti-histone H3                                Abcam                                                            ab1791                                                                                                                                 (1: 5000)

  Antibody                                       rabbit polyclonal anti-histone H3 (Ser10)                        Sigma                                                            06--570                                                                                                                                (1: 500)

  Antibody                                       rabbit polyclonal anti-TDG                                       Active Motif                                                     61437                                                                                                                                  (1: 1000)

  Antibody                                       rabbit polyclonal anti-Caspase-3                                 Cell Signaling                                                   \#9662                                                                                                                                 (1: 1000)

  Antibody                                       rabbit polyclonal anti-Caspase-7                                 Cell Signaling                                                   \#9492                                                                                                                                 (1: 1000)

  Antibody                                       HRP-coupled goat polylonal anti rabbit IgG                       Dianova                                                          111-035-144                                                                                                                            (1: 10000)

  Antibody                                       HRP-coupled goat polyclonal anti mouse IgG                       Dianova                                                          115-035-146                                                                                                                            (1: 10000)

  Recombinant DNA reagent                        pCS2FLAG                                                         Addgene                                                          RRID:[Addgene_16331](https://scicrunch.org/resolver/Addgene_16331)                                                                     

  Recombinant DNA reagent                        pcDNA3.1(+)                                                      Invitrogen                                                       V79020                                                                                                                                 

  Recombinant DNA reagent                        pX330-U6-Chimeric_BB-CBh-hSpCas9                                 Addgene                                                          RRID:[Addgene_42230](https://scicrunch.org/resolver/Addgene_42230)                                                                     

  Recombinant DNA reagent                        pPGKPuro                                                         Addgene                                                          RRID:[Addgene_11349](https://scicrunch.org/resolver/Addgene_11349)                                                                     

  Recombinant DNA reagent                        pCS105-xp53                                                      Stefano Piccolo                                                  NA                                                                                                                                     

  Peptide, recombinant protein                   APE 1                                                            NEB                                                              M0282                                                                                                                                  

  Peptide, recombinant protein                   Endonuclease III (Nth)                                           NEB                                                              M0268                                                                                                                                  

  Commercial assay or kit                        RNeasy Mini Kit                                                  Qiagen                                                           74104                                                                                                                                  

  Commercial assay or kit                        DNeasy Blood and Tissue Kit                                      Qiagen                                                           69504                                                                                                                                  

  Commercial assay or kit                        Blood and Cell Culture DNA Midi Kit                              Qiagen                                                           13343                                                                                                                                  

  Commercial assay or kit                        RNA 6000 Nano kit                                                Agilent                                                          5067--1511                                                                                                                             

  Commercial assay or kit                        Qubit dsDNA HS Assay Kit                                         Invitrogen                                                       Q32851                                                                                                                                 

  Commercial assay or kit                        TruSeq RNA Sample Preparation v2 Kit                             Illumna                                                          RS-122--2001/RS-122--2002                                                                                                              

  Commercial assay or kit                        MEGAscript SP6 Transcription kit                                 Invitrogen                                                       AM1330                                                                                                                                 

  Chemical compound, drug                        Pyocyanin                                                        Sigma                                                            P0046                                                                                                                                  

  Chemical compound, drug                        L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrat          Sigma                                                            A8960                                                                                                                                  

  Chemical compound, drug                        Pifithrin α                                                      Sigma                                                            P4359                                                                                                                                  

  Chemical compound, drug                        NSC 146109                                                       Santa Cruz Biotechnology                                         sc-203652                                                                                                                              

  Chemical compound, drug                        2,6-Di-*tert*-butyl-4-methylphenol (BHT)                         Sigma                                                            B1378                                                                                                                                  

  Chemical compound, drug                        deferoxamine mesylate                                            Sigma                                                            D9533                                                                                                                                  

  Software, algorithm                            LightCycler 480 software                                         Roche                                                            4994884001                                                                                                                             

  Software, algorithm                            bcl2fastq Conversion Software v.1.8.4                            Illumina                                                         <http://emea.support.illumina.com/downloads/bcl2fastq_conversion_software_184.html>                                                    

  Software, algorithm                            FastQC                                                           Babraham Bioinformatics                                          <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>                                                                           

  Software, algorithm                            STAR v.2.5.4b                                                    PMID: [23104886](https://www.ncbi.nlm.nih.gov/pubmed/23104886)                                                                                                                                          

  Software, algorithm                            Subread featureCounts v.1.5.1                                    PMID: [24227677](https://www.ncbi.nlm.nih.gov/pubmed/24227677)                                                                                                                                          

  Software, algorithm                            DESeq2                                                           PMID: [25516281](https://www.ncbi.nlm.nih.gov/pubmed/25516281)                                                                                                                                          

  Software, algorithm                            PANTHER                                                          The Gene Ontology Resource                                       <http://pantherdb.org>                                                                                                                 

  Software, algorithm                            TopHat v. 2.0.9                                                  Johns Hopkins University                                         <https://ccb.jhu.edu/software/tophat/index.shtml>                                                                                      

  Software, algorithm                            iGenomes                                                         Illumina                                                         <http://emea.support.illumina.com/sequencing/sequencing_software/igenome.html>                                                         

  Software, algorithm                            BioVenn                                                          PMID: [18925949](https://www.ncbi.nlm.nih.gov/pubmed/18925949)   <http://www.biovenn.nl/>                                                                                                               

  Software, algorithm                            WebGestalt                                                       PMID: [28472511](https://www.ncbi.nlm.nih.gov/pubmed/28472511)   <http://webgestalt.org/>                                                                                                               

  Software, algorithm                            HTSeq-count v. 0.5.4                                                                                                              <https://htseq.readthedocs.io/en/release_0.11.1/>                                                                                      

  Software, algorithm                            Xenbase                                                          PMID: [29059324](https://www.ncbi.nlm.nih.gov/pubmed/29059324)   <ftp://ftp.xenbase.org/pub/Genomics/JGI/Xenla9.2>                                                                                      

  Software, algorithm                            MassHunter Quantitative Analysis, v. B.05.02                     Agilent Technologies                                             <https://www.agilent.com/en/products/software-informatics/masshunter-suite/masshunter/masshunter-software>                             

  Software,\                                     FACSDiva                                                         BD                                                               <http://www.bdbiosciences.com/en-us/instruments/research-instruments/research-software/flow-cytometry-acquisition/facsdiva-software>   
  algorithm                                                                                                                                                                                                                                                                                                               

  Software, algorithm                            FlowJo software v. 10.5.3                                        BD                                                               <https://www.flowjo.com/solutions/flowjo/downloads/previous-versions>                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Expression constructs {#s4-1}
---------------------

Human *NEIL1*, *NEIL2* and *APEX1* cDNAs (BC010876.1, BC013964.2 and BC008145.1, respectively) were from the ORFeome clone collection. For in vitro transcription *NEIL2* and *APEX1* cDNA was inserted into pCS2FLAG (Addgene plasmid 16331). Additionally, *NEIL1* and *NEIL2* cDNAs were inserted into pcDNA3.1(+) (Invitrogen) as C-terminal (catalytically active) and N-terminal (catalytically inactive) 2xFLAG-tag expression constructs. pCMV-Sport6-xt.bcl2l1 encoding wild type *Xenopus bcl2l1* was purchased from Dharmacon (MXT1765-202788918). pCS105-xp53 encoding wildtype *Xenopus tp53* was a kind gift from S. Piccolo (University of Padua, Italy).

Immunoblotting {#s4-2}
--------------

Western blot analysis of *X. laevis* samples was essentially as described ([@bib54]). Mouse embryoid bodies were incubated in lysate buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 2% NP-40 and Complete Mini Protease Inhibitor Cocktail (Roche)). Lysates were cleared by centrifugation and protein concentrations were estimated by bicinchoninic acid (BCA) assay using BSA as standard followed by SDS-PAGE and western blotting. Antibodies are depicted in key resources table.

Reverse-transcriptase coupled quantitative real time PCR (RT-qPCR) {#s4-3}
------------------------------------------------------------------

Total RNA was prepared by RNeasy Mini Kit (Qiagen) including an on-column DNase digestion according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using SuperScript II reverse transcriptase (Life Technologies). Quantitative real time PCR was performed on a LightCycler 480 (Roche) in technical duplicates using the Universal ProbeLibrary technology (Roche) including the supplier's LightCycler 480 Probes Master. Quantitative analysis was performed with LightCycler 480 software (Roche). Primer sequences and hydrolysis probe numbers are listed in [Supplementary file 6](#supp6){ref-type="supplementary-material"}.

*X. laevis* embryo manipulation and staining {#s4-4}
--------------------------------------------

Animal experiments with *X. laevis* were approved by state authorities (Landesuntersuchungsamt Rheinland-Pfalz, reference number 23177--07/A12-5-001). No blinding or randomization was performed. Embryos were obtained by in vitro fertilization as described ([@bib31]) and cultivated in 0.1x Barth's solution ([@bib108]). Human and *Xenopus* expression constructs as depicted above were used as templates to generate mRNAs with the MEGAscript SP6 Transcription Kit (Invitrogen) according to the manufacturer's instructions. Morpholino antisense oligonucleotides (MOs, see [Supplementary file 6](#supp6){ref-type="supplementary-material"}) were designed to block translation of the respective gene. MOs and mRNAs were injected two times into animal blastomeres at one-cell stage with a total volume of 10 nl per embryo. For overexpression, each embryo was injected with: human *NEIL2* mRNA, 2 ng; *Xenopus tp53* mRNA, 200 pg; *Xenopus bcl2l1* mRNA, 2 ng. Total amounts of single MOs injected per embryo were as follows: *neil2* MO, 40 ng and *tp53* MO, 20 ng. For double MO injections, each embryo was injected with a mixture of 40 ng *neil2* MO and 20 ng *p53* MO. For cartilage staining, one blastomere of two-cell stage embryos was injected with 5 nl (total volume) of *neil2* MO (7.5 ng) and human *NEIL2* mRNA (375 pg). Control mRNA used for injections was *preprolactin*. For ROS induction embryos were grown in 0.1x Barth's solution supplemented with pyocyanin (Sigma, P0046; final concentration 10--25 µM). For Vitamin C treatment embryos were grown in 0.1x Barth's solution supplemented with 100 µM L-Ascorbic acid 2-phosphate (Sigma, A8960). Embryos were fixed at the indicated developmental stage in freshly prepared MEMFA (100 mM MOPS pH 7.4, 2 mM EGTA, 1 mM MgSO~4~, 4% formaldehyde) for 1 hr at RT. After fixation, embryos were washed twice in 100% ethanol at RT for 5 min and stored in 100% ethanol at −20°C. Whole mount in situ hybridization was performed as described ([@bib12]). In situ hybridization probes were generated from cDNAs for *X. laevis* neuronal marker genes, *ccng* and *tp53* using the Dig RNA labeling Kit (Roche). For lineage tracing, *lacZ* mRNA was co-injected (250 pg/blastomere) and β-gal staining was performed as described ([@bib90]) using X-gal as substrate. Neural plates were dissected at stage 14 with Dumont No. five forceps. Cartilage staining was performed as described ([@bib70]). TUNEL assays were carried out as previously described ([@bib42]). Images were taken on a Zeiss SteREO Discovery.V20 microscope.

Cell culture {#s4-5}
------------

Mouse E14TG2a embryonic stem cells (mESCs) were obtained from ATCC, number CRL-1821. Identity has been authenticated by ATCC. E14TG2a were initially tested Mycoplasma-positive, decontaminated using MycoZap Elimination Reagent (Lonza) and subsequently used for the study. E14TG2a cells were cultured on plates coated with 0.1% Gelatin (Millipore) in DMEM supplemented with 15% PANSera ES FBS (PAN Biotech), 2 mM L-Glutamine, 100 µM non-essential amino acids (NEAA, Gibco), 1 mM sodium pyruvate (Gibco), 100 µM 2-mercaptoethanol (Sigma), 1000 U/ml Leukemia inhibitory factor (LIF, Millipore), 100 U/ml PEN-STREP at 37°C in 5% CO~2~ and 20% O~2~.

CRISPR/Cas9-mediated gene deletions {#s4-6}
-----------------------------------

To generate mESCs deficient for *Neil1,2,3, Neil1, Neil2, Neil3, Apex1, Tdg*, and *Neil1/Tdg,* 1 × 10^6^ mESCs were seeded and transfected the next day with either empty or gRNA encoding pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene \#42230) mixed with the selection plasmid pPGKPuro (Addgene \#11349) using Lipofectamine 2000 (Invitrogen) according to manufacturer's instruction. Cells were selected with 2 µg/ml puromycin for 6 days, colonies picked, passaged and subjected to genotyping PCR using primers flanking the anticipated deletion region (see [Supplementary file 6](#supp6){ref-type="supplementary-material"}). Positive clones were expanded for further analyses.

Embryoid body (EB) differentiation {#s4-7}
----------------------------------

3.5 × 10^6^ mESCs were plated on non-adherent 10 cm bacterial dishes (Greiner) in 15 ml CA medium ([@bib9]). CA medium was changed every second day. For retinoic acid induced neural EB differentiation, CA medium was supplemented with all-*trans*-Retinoic acid (R2625, Sigma; final concentration 5 µM) at days 4 and 6 of differentiation. EBs were harvested after 8 days of differentiation. For EB differentiation in presence of ROS inducer pyocyanin (Sigma, P0046; final concentration 2 µM), TP53 stabilizer NSC 146109 (Santa Cruz Biotechnology, sc-203652; final concentration 40 nM) and TP53 inhibitor Pifithrin-α (Sigma, P4359; final concentration 50 µM) drug treatment of cells was started 24 hr prior to plating mESCs on non-adherent dishes and was continued throughout differentiation.

Stable transfection mESCs were transfected with empty vector or human *NEIL1* and *NEIL2* expressing pcDNA3.1 constructs (see 'Expression constructs') using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. Following selection for 6 days with 500 µg/ml G-418 (Gibco) single colonies were picked, expanded in selection medium and analyzed by RT qPCR for expression of the transgene.

Teratoma assay {#s4-8}
--------------

Transplantation of mESCs into immunodeficient (NSG) mice, animal husbandry and tumor preparation was performed by EPO Berlin GmbH. Resulting tumors were split and either shock frozen, or formalin fixed, paraffin embedded, sectioned and stained with hematoxylin and eosin for histological analysis. Tumors from each three independent control and *Neil1,2,3*^−/−^ mESC lines were grown in technical triplicates.

RNA sequencing {#s4-9}
--------------

### Frog embryos {#s4-9-1}

Control MO and *neil2* MO-injected *Xenopus laevis* embryos in triplicates (n ≥ 5 per batch of embryo) at stage 23 were lysed with 700 μl Qiazol reagent and homogenized by pipetting. After 5 min incubation at room temperature, 200 μl chloroform was added and samples were shaken vigorously. RNA was isolated subsequently using a Qiagen RNeasy Mini Kit according to the manufacturer's instructions. RNA integrity was validated using an RNA 6000 Nano kit on an Agilent 2100 Bioanalyzer. NGS library preparation was performed using Illumina\'s TruSeq RNA Sample Preparation v2 Kit followed the standard protocol. Libraries were prepared with a starting amount of 1 μg, amplified in 12 PCR cycles, profiled in a DNA 1000 chip on an Agilent 2100 Bioanalyzer and quantified using the Qubit dsDNA HS Assay Kit in a Qubit 2.0 Fluorometer (Life Technologies). All six libraries were pooled in equimolar ratio and sequenced on HiSeq 2000 in single read mode for 50 cycles plus additional eight cycles for the index read. Sample demultiplexing and FastQ file generation was performed using Illumina\'s bcl2fastq Conversion Software v.1.8.4. The raw sequence reads were quality assessed using FastQC (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and aligned to the *Xenopus laevis* v.9.2 genome assembly with JGI gene annotation from Xenbase (<ftp://ftp.xenbase.org/pub/Genomics/JGI/Xenla9.2>) using STAR v.2.5.4b ([@bib26]) with option '\--outFilterMismatchNmax 2'. The mapped reads were summarised on the gene level using Subread featureCounts v.1.5.1 ([@bib62]) with default parameters. Differential gene expression analysis was performed with the Bioconductor package DESeq2 v.1.18.1 ([@bib65]) following the recommended analysis workflow with independent gene filtering. Differentially expressed genes were identified using a statistical cutoff of 10% false discovery rate (FDR) and an effect size filter 'log2 fold change (FC)' above 0.5. Differentially expressed up- and downregulated genes at log2FC \>1 were subjected to pathway enrichment analysis with PANTHER (<http://pantherdb.org>) using the *Xenopus laevis* gene symbols without L/S alloallele suffixes, background list of all DESeq2-tested genes, human pathway annotation and the default enrichment cutoff of 5% FDR.

### Mouse cells {#s4-9-2}

Snap frozen teratomas derived from each three control and *Neil1,2,3*^−/−^ mESC lines in triplicates were homogenized with an Ultra-TURRAX disperser (IKA) in presence of 2 ml TRIzol reagent (Invitrogen) using \~200 mg tissue per tumor. After clearance of supernatant by centrifugation for 5 min at 12.000 x g at 4°C, 0.4 ml of chloroform was added and the solution centrifuged for 15 min at 12.000 x g at 4°C. RNA from the aqueous phase was precipitated with 1 ml isopropanol, washed with 75% ethanol, air dried and resuspended in RNase-free water. Contaminating DNA was digested with DNase I followed by an RNA cleanup (RNeasy kit, Qiagen) according to manufacturer's instructions. Total RNA from control, *Neil1*^−/−^, *Neil2*^−/−^ mESCs, EBs and EBs+RA in biological triplicates and *Apex1*^−/−^ mESCs, EBs and EBs + RA in technical duplicates was isolated using the Qiagen RNeasy Mini Kit according to the manufacturer's instructions, including on-column DNase I digest.

RNA was quantified with a Thermo NanoDrop and quality tested on Agilent 2100 Bioanalyzer. Only samples with RIN values \> 9 were used for RNA-seq. NGS libraries were prepared from total RNA using the TruSeq RNA Sample Prep Kit v2 (Illumina) according to the manufacturer's recommendations and amplified in 12 PCR cycles. Libraries were profiled in a High Sensitivity DNA chip on a 2100 Bioanalyzer and quantified using the Qubit dsDNA HS Assay Kit, in a Qubit 2.0 Fluorometer (Life Technologies). The NGS libraries were sequenced on a HiSeq 2000 Illumina sequencer, for 51 cycles plus seven cycles for the index read. Raw reads were quality assessed using FastQC (<https://www.bioinformatics.babraham.ac.uk/projects/> fastqc/) and mapped to the mouse genome assembly NCBIM37/mm9 using TopHat v. 2.0.9 (<https://ccb.jhu.edu/software/tophat>) and a GTF gene annotation file from Illumina iGenomes. HTSeq-count v. 0.5.4 (<https://htseq.readthedocs.io/en/release_0.11.1/>) was used for summarizing the mapped reads on genes. The Bioconductor package DESeq2 (<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>) was used to identify genes with significant differential expression in *Neil1,2,3*^−/−^ teratomas, and *Neil1*, *Neil2* and *Apex1* single-knockout samples compared to the control samples with a statistical cutoff of 10% false discovery rate (FDR) and an effect size filter log2FC \> 0.5. Overlap of differentially expressed genes was created with BioVenn ([@bib47]). Pathway enrichment analysis was performed with WebGestalt ([@bib109]) using 'Wikipathway' as functional database with the default 5% FDR enrichment cutoff, differentially expressed up- and downregulated genes at log2FC \> 1 and background list of all DESeq2-tested genes.

The RNA-seq datasets have been deposited in the NCBI GEO database under accession number GSE130082.

Preparation of genomic, mitochondrial and synthetic DNA for LC-MS/MS analysis {#s4-10}
-----------------------------------------------------------------------------

Genomic DNA for analysis of 5mC, 5hmC, 5fC and 5caC was prepared using the DNeasy Kit (Qiagen) according to manufacturer's instructions.

Genomic DNA for abasic site analysis was prepared with the Qiagen Blood and Cell Culture DNA Midi Kit essentially as described ([@bib78]) but using buffers G2, QC, QF supplemented with each 400 µM of the antioxidants 2,6-Di-*tert*-butyl-4-methylphenol (BHT, Sigma B1378) and deferoxamine mesylate (DFOM, Sigma D9533). DNA was stored at −20°C in H~2~O supplemented with 40 µM BHT and DFOM.

Preparation of mtDNA was performed using the QIAprep Spin Miniprep Kit (Qiagen) following manufacturer's instructions. Buffers P1, P2, N3, PB and PE were supplemented with 400 µM BHT and DFOM. DNA was eluted with H~2~O containing 40 µM BHT and DFOM. Quantitative real time PCR as described above was used to calculate the enrichment of mtDNA over gDNA by the ΔΔCp method ([@bib77]). PCR mixture contained 1 ng of DNA and gDNA- and mtDNA-specific primers (mmActB and mmCytB, see [Supplementary file 6](#supp6){ref-type="supplementary-material"} for sequences).

Endogenous abasic sites on genomic and mtDNA (3 µg each) were processed by incubation with 20 units APE 1 (NEB, M0282) in a 50 µl reaction volume for 2 hr at 37°C. After phenol/chloroform extraction, DNA was further incubated with 20 units Endonuclease III (Nth, NEB, M0268) in a 50 µl reaction volume for 2 hr at 37°C, phenol/chloroform extracted, ethanol precipitated and resuspended in H~2~O supplemented with 40 µM BHT and DFOM.

Synthetic oligonucleotides were resuspended in H~2~O supplemented with 40 µM BHT and DFOM. The unmodified (40mer) and 5hU-containing oligo (40mer_5hU) were hybridized in 1x SSC (150 mM NaCl, 15 mM trisodium citrate, pH 7.0) to the complementary strand (40mer_complementary) in a 1:1 molar ratio. For abasic site production 500 pmoles of the single-stranded uracil-containing oligo (40mer_U) were incubated with 25 units UDG (NEB, M0280) in a 50 µl reaction volume for 30 min at 37°C. After phenol/chloroform extraction and ethanol precipitation the abasic site oligo was hybridized to the complementary strand as described above. APE 1- and Endonuclease III-treatment was performed as depicted above with 3 µg of double-stranded oligonucleotides. DNA was purified by phenol/chloroform, ethanol precipitated and resuspended in H~2~O supplemented with 40 µM BHT and DFOM for abasic site derivatization as outlined below. Oligonucleotide sequences are listed in [Supplementary file 6](#supp6){ref-type="supplementary-material"}.

Quantitative mass spectrometry (LC-MS/MS) {#s4-11}
-----------------------------------------

Quantification of 5mC and oxidative derivatives was carried out as described before ([@bib86]).

Quantification of abasic sites by LC-MS/MS was performed according to the published protocol ([@bib78]) with specific changes: Derivatization was performed with 1--2 µg of DNA and 30 nmoles of reagent 1a for 60 min at 37°C. After an additional incubation with 30 nmoles of reagent 1a for 60 min at 37°C reaction was stopped, the DNA ethanol precipitated, dissolved in 15 µl H~2~O and digested as described ([@bib86]). After digest, DNA was mixed with an equal volume of isotopic standards, and 5 μL were injected for LC-MS/MS analysis. The chromatographic separation was performed on a ZORBAX SB-C18 column (Agilent, 5 μm, 2.1 ×50 mm). Elution was performed with 5 mM Ammonium acetate pH 6.9 and Acetonitrile (ACN), the flow rates were 0.4 ml/min for 0--7 min, 0.5 ml/min for 7--9 min and 0.4 ml/min for 9--10 min at 30°C with the following gradient: 0--2 min, 0% ACN; 2--5 min, 0--5% ACN; 5--9 min, 5--50% ACN; 9--10 min, 0% ACN. Transitions corresponding to dG, 9a_1, 10a_1 and their respective isotopic standards ^15^N~5~-dG, 9b_1, 10b_1 were monitored (for compounds 9a_1, 9_b1, 10_a1, 10_b1 see [@bib78]). The source‐dependent parameters were as follow: gas temperature 110°C, gas flow 19 l/min (N~2~), Nebulizer 25 psi, sheath gas heater 375°C, sheath gas flow 11 l/min (N~2~), capillary voltage 2000 V (positive mode), nozzle voltage 0 V, fragmentor voltage 300 V. Compound dependent parameters were as previously described ([@bib78]) except that MS1 resolution for dG and ^15^N~5~-dG were enhanced and MS2 was unit. For the rest of ions all MS1 and MS2 resolution were set to unit. Abasic sites were initially quantified over total dG and subsequently calculated over total N using a GC content of 42% of the mouse genome.

Detection of mtDNA damage by quantitative PCR {#s4-12}
---------------------------------------------

Preparation of mtDNA was performed as described above. Quantitative PCR was essentially as described ([@bib33]) using 500 pg of mtDNA on a LightCycler 480 (Roche) in technical duplicates. Short fragments were amplified each with 20 s, long fragments with 2 min elongation steps in 35 cycles. SYBR Green was from Sigma (S9430). Calculation of lesions per 10 kb was as described ([@bib33]). For primer sequences and amplicon lengths see [Supplementary file 6](#supp6){ref-type="supplementary-material"}.

Flow cytometry analysis {#s4-13}
-----------------------

Cells were detached using 0.25% trypsin and washed with PBS containing 1% ESC grade FBS. Cells were fixed by adding dropwise ice-cold ethanol and subsequent incubation at −20°C for 30 min or storage at this point. For propidium iodide staining, cells were washed twice with PBS containing 0.1% ESC grade FBS and 100 µg/ml RNAse A (Qiagen). Cells were then resuspended in PBS containing 50 µg/ml propidium iodide (Sigma) according to the cell number and incubated at room temperature for 10 min in the dark. Stained cells were then analysed by the BD LSRFortessaSORP flow cytometry system using FACSDiva software. Data analysis was performed with FlowJo software v. 10.5.3 (BD).

Statistical analysis {#s4-14}
--------------------

Data presented are displayed as arithmetic mean, error bars represent standard deviations (s.d.) of the indicated replicates. Statistical significance as shown in bar diagrams was determined by two-tailed unpaired Student's t-test. Significance of overlapping groups of genes presented in Venn Diagrams was calculated by hypergeometric distribution (<http://nemates.org/MA/progs/overlap_stats.html>) using a total number of 17 000 expressed genes per calculation. In triple overlaps significance was calculated on the basis of commonly deregulated genes in *Neil1* and *Neil2*-deficient cells. Significances are displayed as \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.005. NS, not significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"NEIL1 and NEIL2 DNA glycosylases protect neural crest development against mitochondrial oxidative stress\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Marianne Bronner as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Eliezer Calo (Reviewer \#1); Fadel Tissir (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, Han et al. investigate the role of NEIL family bifunctional DNA glycosylases/lyases in *Xenopus* embryos and differentiating mouse embryonic stem cells (mESCs). They find that in *Xenopus* embryos Neil2 deficiency leads to defects in cranial neural crest cell development and link this to an oxidative stress-induced TP53-dependent mitochondrial DNA damage response that leads to apoptosis. They then use mESCs to confirm similar findings in mammalian cells. They suggest a model whereby NEIL1/NEIL2 function to repair and protect the mitochondrial genome against oxidative damages that accompany the metabolic switch upon neural differentiation. The manuscript presents an interesting connection between mitochondria oxidative stress and neural crest differentiation defects. As presented however, the study needs to be strengthened.

Essential revisions:

1\) The authors must drop the claim that there is an effect on neural differentiation in *Xenopus* or do the work needed to validate this claim. e.g. look at multiple markers at both neural plate stages and later tailbud stages at neural differentiation markers.

2\) The authors must use multiple markers in mESCs to validate effects on neural crest and neural differentiation.

3\) The authors should examine *tp53* expression in NEIL2 morphants and pyocyanin treated embryos and for pyocyanin treated embryos drug treatment should be done more proximal to the time of neural crest/neural plate formation.

4\) More rigorous validation of the CRISPR-Cas9 mutations is needed.

5\) The authors need to provide additional evidence demonstrating that the oxidative stress response directly causes the phenotype and originates in the mitochondria. To me this is the most novel aspect of the work.

The full reviews are attached to provide further details, which we advise you to address if possible.

Reviewer \#1:

This is an intriguing study that reveals how DNA glycosylases, particularly Neil1 and Neil2, protect neural crest cells from oxidative damage to mitochondrial DNA. The most novel aspect of this work is the connection between mitochondria oxidative stress and neural crest differentiation defects. As presented however, the work lacks mechanism and need to be strengthened before this manuscript is accepted for publication. Below I propose some experiments to strengthen the conclusions of the manuscript.

1\) The authors developed a method to detect abasic sites generated by oxidative stress. While useful and informative, there\'s no validation of this method. How do we know that this method works as intended?

2\) The authors should use an alternative experimental approach to confirm that the oxidative stress response is restricted to the mitochondrial genome.

3\) If oxidative stress in the mitochondria is the major cause of the craniofacial phenotype, then mitochondrial disfunction should be evident in the Neil1/2 mutant background upon neuroectoderm induction. Experimental evidence for this is lacking.

4\) Most of the mechanistic data derived from the interpretation of gene expression analyses. I found these data supportive, but unconvincing. There is a wealth of commercially available antibodies/reagents to study intrinsic apoptosis. The authors should leverage these reagents to solidify their conclusions.

Lastly, many statements throughout the paper are not accurate and therefore misleading to the reader. Also, the authors are very selective of the literature they chose to reference.

Reviewer \#2:

In this manuscript, Dandan Han, Christof Niehrs and colleagues describe a mechanism whereby glucosylases NEIL1 and NEIL2 protect cranial neural crest cells (cNCC) against oxidative DNA (particularly mitochondrial DNA) damage. They used a used a series of morpholino-mediated downregulations in *Xenopus*, and Crispr/Cas9 knockouts in the mouse embryonic stem cells and convincingly show that the disruption of NEIL glucosylases (mainly 1 and 2) induces a Tp53 DNA damage response and results in differentiation defects of cNCC. The amount of data is impressive and the quality is very high.

I have only one major point that needs to be addressed experimentally and few other points that should be clarified in the text.

The validation of the mESCs Ko is incomplete/insufficient. Western blots for many targeted proteins (Neil2 and 3). The off-target effect inherent to CRISPR/Cas9 is a real issue both in the literature and in this study as well (see for instance Figure 6---figure supplement 1B that shows that 2 distinct deletions occur in a small region (+ 1kb) amplified by PCR in the triple Ko -- Introduction). Whole genome sequencing is the only reliable way to rule out the possibility of off target mutations. At least uncropped gel images for all the KO cells have to be shown.

Reviewer \#3:

In this manuscript Han et al. investigate the role of NEIL family bifunctional DNA glycosylases/lyases in *Xenopus* embryos and differentiating mouse embryonic stem cells (mESCs). They find that in *Xenopus* embryos Neil2 deficiency leads to defects in cranial neural crest cell development and link this to an oxidative stress-induced TP53-dependent mitochondrial DNA damage response that leads to apoptosis. They then use mESCs to confirm similar findings in mammalian cells. They suggest a model whereby NEIL1/NEIL2 function to repair and protect the mitochondrial genome against oxidative damages that accompany the metabolic switch upon neural differentiation. The work in this manuscript is, for the most part, well executed and the findings are potentially of broad interest. A problem that persists throughout the work, however, is the conflating of cranial neural crest formation/development with neural differentiation, which is confusing and detracts from the impact of the work. This is particularly odd given that they one late phenotype that the authors examine is craniofacial cartilage, which is clearly not an example of neural differentiation.

From the *Xenopus* work it appears that the main finding is that NEIL2 morphants and pyocyanin treated embryos show a loss of neural crest markers at neurula stages and that this ultimately results in a loss of neural crest derivatives as evidenced by the cartilage phenotype. The authors link this to an increase in tp53, and show that tp53 over-expression also leads to a decrease in neural crest markers. Oddly, the authors conclude from this that \"the cNCC defects in Neil2 morphants reflect a \"neural-restricted Tp53-response to oxidative DNA damage\". However they look at Sox3 expression in the neural plate and it is relatively normal. If the authors wish to extend their conclusions to neural rather than neural crest development then they need to look at a broader range of neural markers, including at later stages. In the absence of this, they can really only make conclusions about neural crest cells.

The experiments with pyocyanin are problematic as the treatment appears to have been from early cleavage stages so any effects on neural crest could be very indirect -- what happens if you treat later, for example at gastrulation?

In Figure 1H the authors preclude an effect on proliferation using a western blot for p-H3 but one would not likely detect local effects by this assay -- they should do whole mount staining

Tunnel staining in Figure 1J shows increased apoptosis in both neural and non-neural cells but the authors state that cell death is in neural cells.

It is interesting that p53 expression is elevated at the neural folds relative to other tissues. One might think that would render these cells more rather than less protected against oxidative stress than their neighbors. The authors should comment on this. Also what happens to p53 expression in Neil2 morphants or after pyocyanin treatment?

The authors see a decrease in Slug expression after tp53 injection, but not loss of the lineage tracer β-galactosidase, so the cells are presumably still there. This call into question whether the decrease observed is really cell death dependent. They should block apoptosis with Bcl2 and determine if expression is rescued. Also given the authors continued focus on neural differentiation, does p53 injection alter sox3 expression or other neural markers such as neural tubulin?

In the second half of the paper focusing on mESCs the authors interpret their findings as requirement for NEIL function in cNCC development is evolutionarily conserved between amphibians and mammals. However they draw this conclusion without convincing data for neural phenotypes in *Xenopus* and using only one marker each for neural and neural crest (Pax6/Pax3). Multiple markers for each cell type should be examined.

10.7554/eLife.49044.038

Author response

> Essential revisions:
>
> 1\) The authors must drop the claim that there is an effect on neural differentiation in Xenopus or do the work needed to validate this claim. e.g. look at multiple markers at both neural plate stages and later tailbud stages at neural differentiation markers.

We agree and we now emphasize that the phenotype of Neil2-morphant *Xenopus* is specific to cNCC- but not to neural differentiation.

> 2\) The authors must use multiple markers in mESCs to validate effects on neural crest and neural differentiation.

We have now added three additional markers for neural crest (*Hoxa2, Tfapb2, Neurog1*) and neural (*Nestin, Sox1, Pax2*) differentiation supporting our conclusion about cNCC and neural differentiation defects in *Neil1*- and *Neil2*-deficient mESCs. The results are presented in Figure 6---figure supplement 2 and Figure 7---figure supplement 2.

> 3\) The authors should examine tp53 expression in NEIL2 morphants and pyocyanin treated embryos.

We now performed *tp53* expression analysis in stage 14 Neil2 morphants and pyocyanin-treated embryos. Tp53 expression is significantly elevated in both cases albeit less strong when compared to Tp53 target genes (Figure 1F and 3B).

> And for pyocyanin treated embryos drug treatment should be done more proximal to the time of neural crest/neural plate formation.

We treated embryos with pyocyanin from stage 8.5 and 10 onwards and with different doses (25 and 80 µM) but could not detect a Tp53 DDR at stage 14/15 nor any strong phenotype at stage 32 (data not shown) with the exception of high dose pyocyanin from stage 8.5 onwards. The time may be too short for sufficient oxidative DNA damage accumulation and full Tp53 cascade induction. In addition, we showed that *neil2* expression is temporally restricted in *Xenopus* embryos until stage 10 (PMID: 26751644) indicative of a critical requirement for Neil2 in lesion repair in early stages prior to neural crest development. Hence, we conclude that to mimic Neil2-deficiency, Pyocyanin treatment needs to start from early stages onwards.

> 4\) More rigorous validation of the CRISPR-Cas9 mutations is needed.

1\) We previously validated the knockouts in all generated cell lines by several means:

i\) Genotyping PCR on gDNA with primers spanning the anticipated deletion region as presented in Figure 6---figure supplement 1, Figure 7---figure supplement 1, Figure 8---figure supplement 1, Figure 9---figure supplement 1 and Figure 9---figure supplement 2 (now also shown as uncropped agarose gels).

ii\) Western blot analysis for endogenous proteins if antibodies were available and working (NEIL1 in Figure 6---figure supplement 1 and Figure 7---figure supplement 1, APEX1 in Figure 8---figure supplement 1, and TDG in Figure 9---figure supplement 1 and Figure 9---figure supplement 2).

iii\) RT-qPCR for expression analysis of the targeted exons (Neil2 and Neil3, Figure 6---figure supplement 1, Figure 7---figure supplement 3). Together, these analyses unambiguously confirmed the anticipated knockouts in the respective lines.

2\) We now analyzed with CRISPOR (PMID: 27380939) off-target probability and potential off-target regions of the 6 gRNAs used to generate the *Neil1, Neil2* and *Apex1* knockout lines. These are the cell lines that showed neural and cNCC differentiation defects and were subjected to RNAseq analysis as undifferentiated mESCs. All 6 gRNAs were scored \>75 in the CFD specificity score (scale from 0 -- 100, the higher the specificity score, the lower the probability for off-targets in the genome). In addition, we found among the potential off-target regions 25 genes with exonic matches for the two *Neil1* gRNAs, 14 for *Neil2* and 12 for *Apex1* all of which had between 3-4 base mismatches. Frameshift mutations are frequently accompanied by RNA level deregulation due to non-sense mediated decay or compensatory upregulation, respectively. However, only 4 of the 51 total candidates showed slight (log2FC \<1.0) RNA deregulation in the respective knockout lines compared to control mESCs (data not shown).

3\) Most importantly, stable expression of *NEIL1* and *NEIL2* in the respective *Neil1* and *Neil2* knockout lines rescued the neural and neural crest differentiation defects (Figure 7---figure supplement 3) showing the specificity of the knockout approach.

> 5\) The authors need to provide additional evidence demonstrating that the oxidative stress response directly causes the phenotype and originates in the mitochondria. To me this is the most novel aspect of the work.

1\) We now performed L-ascorbic acid (Vitamin C) antioxidant treatment of *neil2* MO-injected *Xenopus* embryos. Vitamin C partially rescued the severe phenotype induced by Neil2-deficiency supporting the link between the neural crest phenotype and oxidative stress (Figure 3G).

2\) We now confirmed elevated mtDNA damage in *Neil1* and *Neil2*-deficient EBs + RA (Figure 11C) by a mass spectrometry-independent approach based on quantitative PCR for damage detection (PMID: 28286206). In this long-range PCR, levels of DNA damage are monitored based on the fact that DNA lesions inhibit DNA polymerase and slow down accumulation of the PCR product. Therefore, the rate of product amplification is inversely proportional to the number of damaged DNA molecules. The results shows damage accumulation notably under RA-induced neural differentiation but not in undifferentiated mESCs, corroborating our conclusions.

3\) Mutations on mtDNA and subsequent mitochondrial dysfunction result in compensatory upregulation of mitochondrial OXPHOS genes (PMID: 10438462, 19389473). Hence, we monitored the expression of a number of mitochondrial OXPHOS genes in both model systems, *Xenopus* and mESCs, and found a systematic upregulation of these genes in Neil2-deficient *Xenopus* embryos as well as *Neil1-* and *Neil2*-deficient mESCs during neural differentiation (Figure 2C and 11D). The result supports the notion that the stress response leads to mitochondrial dysfunction following mtDNA damage.

4\) We have validated the mass spectrometry-based quantification of abasic sites (PMID: 28715893) and oxidative base damages using synthetic oligonucleotides with defined amounts of lesions. The result confirms the approach to function as intended (presented in Figure 11---figure supplement 1C). Hence, the quantification of base damages on cellular DNA (Figure 11B) is reliable.

> The full reviews are attached to provide further details, which we advise you to address if possible.
>
> Reviewer \#1:
>
> \[...\] 1) The authors developed a method to detect abasic sites generated by oxidative stress. While useful and informative, there\'s no validation of this method. How do we know that this method work as intended?

We have validated the mass spectrometry-based quantification of abasic sites (PMID: 28715893) and oxidative base damages using synthetic oligonucleotides with defined amounts of lesions. The result confirms the approach to function as intended (presented in Figure 11---figure supplement 1C). Hence, the quantification of base damages on cellular DNA (Figure 11B) is reliable.

> 2\) The authors should use an alternative experimental approach to confirm that the oxidative stress response is restricted to the mitochondrial genome.

We added further evidence for elevated mtDNA damage in *Neil1* and *Neil2*-deficient EBs + RA (Figure 11C) by a mass spectrometry-independent approach based on quantitative PCR for damage detection (PMID: 28286206). In this long-range PCR, levels of DNA damage are monitored based on the fact that DNA lesions inhibit DNA polymerase and slow down accumulation of the PCR product. Therefore, the rate of product amplification is inversely proportional to the number of damaged DNA molecules. The results shows damage accumulation notably under RA-induced neural differentiation but not in undifferentiated mESCs, corroborating our conclusions.

> 3\) If oxidative stress in the mitochondria is the major cause of the craniofacial phenotype, then mitochondrial disfunction should be evident in the Neil1/2 mutant background upon neuroectoderm induction. Experimental evidence for this is lacking.

We now show elevated mt gene expression indicative of mitochondrial dysfunction in both model systems, *Xenopus* and mESCs (Figure 2C and 11D).

> 4\) Most of the mechanistic data derived from the interpretation of gene expression analyses. I found these data supportive, but unconvincing. There is a wealth of commercially available antibodies/reagents to study intrinsic apoptosis. The authors should leverage these reagents to solidify their conclusions.
>
> We did utilize a variety of antibodies (targeting Caspase-3, Caspase-7, Caspase-9, AIF, Cytochrome C) to confirm an intrinsic apoptosis pathway in EB + RA differentiated cells. However, by Western blot we could not detect substantial activation or translocation of these apoptotic factors in *Neil*-knockout- as compared to control clones (Figure 12---figure supplement 2B). This could be due to insufficient sensitivity in a whole-population analysis with a fraction of cells being affected. Instead, we detected and confirmed a requirement for Caspase-3 (cleaved and uncleaved) during neuronal differentiation (Figure 12 ---figure supplement 2A) indicative of a systemic regulation of apoptotic factors. Moreover, TP53 target gene activation in EB + RA cells was moderate (\< 2-fold) though significant as assessed by RT-qPCR analysis (Figure 12D and Figure 12---figure supplement 1C). Importantly, we now show a rescue of the Neil2 MO-induced phenotype by *bcl2l1* overexpression in *Xenopus* embryos confirming ongoing intrinsic apoptosis by *Neil2*-deficiency (Figure 2A-B).
>
> Lastly, many statements throughout the paper are not accurate and therefore misleading to the reader. Also, the authors are very selective of the literature they chose to reference.

We apologize for the missing accuracy and tried our best to improve the manuscript text and references, see below.

> Reviewer \#2:
>
> \[...\] I have only one major point that needs to be addressed experimentally and few other points that should be clarified in the text.
>
> The validation of the mESCs Ko is incomplete/insufficient. Western blots for many targeted proteins (Neil2 and 3). The off-target effect inherent to CRISPR/Cas9 is a real issue both in the literature and in this study as well (see for instance Figure 6---figure supplement 1B that shows that 2 distinct deletions occur in a small region (+ 1kb) amplified by PCR in the triple Ko -- Introduction). Whole genome sequencing is the only reliable way to rule out the possibility of off target mutations. At least uncropped gel images for all the KO cells have to be shown (I\'m happy to hear from other reviewers and editors on this point).

We agree that potential off-target effects are an issue in CRISPR/Cas9 genome editing, and did further analysis.

1\) We previously validated the knockouts in all generated cell lines by several means:

i\) Genotyping PCR on gDNA with primers spanning the anticipated deletion region as presented in Figure 6---figure supplement 1, Figure 7---figure supplement 1, Figure 8---figure supplement 1, Figure 9---figure supplement 1 and Figure 9---figure supplement 2 (now also shown as uncropped agarose gels).

ii\) Western blot analysis for endogenous proteins if antibodies were available and working (NEIL1 in Figure 6---figure supplement 1 and Figure 7---figure supplement 1, APEX1 in Figure 8---figure supplement 1, and TDG in Figure 9---figure supplement 1 and Figure 9---figure supplement 2).

iii\) RT-qPCR for expression analysis of the targeted exons (Neil2 and Neil3, Figure 6---figure supplement 1, Figure 7---figure supplement 3). Together, these analyses unambiguously confirmed the anticipated knockouts in the respective lines.

2\) We now analyzed with CRISPOR (PMID: 27380939) off-target probability and potential off-target regions of the 6 gRNAs used to generate the *Neil1, Neil2* and *Apex1* knockout lines. These are the cell lines that showed neural and cNCC differentiation defects and were subjected to RNAseq analysis as undifferentiated mESCs. All 6 gRNAs were scored \>75 in the CFD specificity score (scale from 0 -- 100, the higher the specificity score, the lower the probability for off-targets in the genome). In addition, we found among the potential off-target regions 25 genes with exonic matches for the two *Neil1* gRNAs, 14 for *Neil2* and 12 for *Apex1* all of which had between 3-4 base mismatches. Frameshift mutations are frequently accompanied by RNA level deregulation due to non-sense mediated decay or compensatory upregulation, respectively. However, only 4 of the 51 total candidates showed slight (log2FC \<1.0) RNA deregulation in the respective knockout lines compared to control mESCs (data not shown).

3\) It is not surprising to see two distinct bands when deleting a target region of a gene in both alleles with two gRNAs since the error prone non-homologous end-joining will most likely produce different repair outcomes at the two allelic loci. Two PCR bands are also detectable with the *Neil1* single-knockout clone \#11 (Figure 7---figure supplement 1A). Such a result is not a sign of off-target effects of the gRNAs. Notably, most of the genotyping PCRs generated apparently a unique deletion band; however, it is more likely that such bands consist of two different PCR products with similar length not resolvable by an agarose gel. To this end, we sequenced the apparent single band PCR products of all three *Neil2* single knockout clones (as shown in Figure 7---figure supplement 1A) and could indeed reveal twice two distinct sequences:

Neil2 \#1

5'ACACTATAGTGATTAGTATTTGCTG\-\--615bp\-\--ATGACCCCACGCAGGATCAGAAGAA 3'

5'TAGTATTTGCTGTGTGGTTAAGGCT\-\--587bp\-\--AAAAGGATGGACCTGATGACCCCAC 3'

Neil2 \#11

5'GTATTTGCTGTGTGGTTAAGGCTGA\-\--586bp\-\--AAAGGATGGACCTGATGACCCCACG 3'

Neil2 \#14

5' AAGACTCTGTCTTAACCAACCAAAC\-\--695bp\-\--AAGGATGGACCTGATGACCCCACGC 3'

5' TGATTAGTATTTGCTGTGTGGTTAA\-\--594bp\-\--AGGATGGACCTGATGACCCCACGCA 3'

4\) Most importantly, stable expression of *NEIL1* and *NEIL2* in the respective *Neil1* and *Neil2* knockout lines rescued the neural and neural crest differentiation defects (Figure 7---figure supplement 3) showing the specificity of the knockout approach.

> Reviewer \#3:
>
> \[...\] A problem that persists throughout the work, however, is the conflating of cranial neural crest formation/development with neural differentiation, which is confusing and detracts from the impact of the work. This is particularly odd given that they one late phenotype that the authors examine is craniofacial cartilage, which is clearly not an example of neural differentiation.
>
> From the Xenopus work it appears that the main finding is that NEIL2 morphants and pyocyanin treated embryos show a loss of neural crest markers at neurula stages and that this ultimately results in a loss of neural crest derivatives as evidenced by the cartilage phenotype. The authors link this to an increase in tp53, and show that tp53 over-expression also leads to a decrease in neural crest markers. Oddly, the authors conclude from this that \"the cNCC defects in Neil2 morphants reflect a \"neural-restricted Tp53-response to oxidative DNA damage\". However they look at Sox3 expression in the neural plate and it is relatively normal. If the authors wish to extend their conclusions to neural rather than neural crest development then they need to look at a broader range of neural markers, including at later stages. In the absence of this, they can really only make conclusions about neural crest cells.

We agree and we now emphasize that the phenotype of Neil2-morphant *Xenopus* is specific to cNCC- but not to neural differentiation.

> The experiments with pyocyanin are problematic as the treatment appears to have been from early cleavage stages so any effects on neural crest could be very indirect -- what happens if you treat later, for example at gastrulation?
>
> We treated embryos with pyocyanin from stage 8.5 and 10 onwards and with different doses (25 and 80 µM) but could not detect a Tp53 DDR at stage 14/15 nor any strong phenotype at stage 32 (data not shown) with the exception of high dose pyocyanin from stage 8.5 onwards. The time may be too short for sufficient oxidative DNA damage accumulation and full Tp53 cascade induction. In addition, we showed that *neil2* expression is temporally restricted in *Xenopus* embryos until stage 10 (PMID: 26751644) indicative of a critical requirement for Neil2 in lesion repair in early stages prior to neural crest development. Hence, we conclude that to mimic Neil2-deficiency, Pyocyanin treatment needs to start from early stages onwards.
>
> In Figure 1H the authors preclude an effect on proliferation using a western blot for p-H3 but one would not likely detect local effects by this assay -- they should do whole mount staining.

We performed p-H3 whole mount immunoassays in Neil2 morphant embryos in our previous study (PMID: 26751644). The result is congruent with the western blot shown in the current study.

> Tunnel staining in Figure 1J shows increased apoptosis in both neural and non-neural cells but the authors state that cell death is in neural cells.

We did not conclude from Figure 1J that apoptosis is restricted to neural cells: "Whole mount TUNEL assay of unilaterally neil2 MO-injected embryos confirmed elevated apoptosis by Neil2-deficiency in stage 16 embryos (Figure 1J)." However, we concluded from the western blot shown in Figure 1I that cleaved Caspase-3 levels (apoptosis) were elevated in neural- compared to non-neural tissues.

> It is interesting that p53 expression is elevated at the neural folds relative to other tissues. One might think that would render these cells more rather than less protected against oxidative stress than their neighbors. The authors should comment on this.

We state in the Discussion:

"Neurogenesis is accompanied by a metabolic switch from glycolysis to oxidative phosphorylation, a concomitant increase in mass and number of mitochondria per cell, and hence escalated oxidative stress (Khacho and Slack, 2018). \[...\] Hence, cells with high basal Tp53 expression will reach detrimental Tp53 levels more easily upon stress."

> Also what happens to p53 expression in Neil2 morphants or after pyocyanin treatment?

Tp53 expression is significantly elevated in both cases albeit less strong when compared to Tp53 target genes (Figure 1F and 3B).

> The authors see a decrease in Slug expression after tp53 injection, but not loss of the lineage tracer β-galactosidase, so the cells are presumably still there. This call into question whether the decrease observed is really cell death dependent. They should block apoptosis with Bcl2 and determine if expression is rescued. Also given the authors continued focus on neural differentiation, does p53 injection alter sox3 expression or other neural markers such as neural tubulin?

*Bcl2l1* (the *Xenopus Bcl2* homologue) mRNA injection indeed rescued *Neil2* MO-triggered malformations as well as elevated levels of cleaved Caspase-3 in neural tissues (new Figure 2A-B) supporting induced apoptosis by Neil2-deficiency in *Xenopus*, and a functional link between apoptosis and the observed malformations.

> In the second half of the paper focusing on mESCs the authors interpret their findings as requirement for NEIL function in cNCC development is evolutionarily conserved between amphibians and mammals. However they draw this conclusion without convincing data for neural phenotypes in Xenopus and using only one marker each for neural and neural crest (Pax6/Pax3). Multiple markers for each cell type should be examined.

We have now added three additional markers for neural crest (*Hoxa2, Tfapb2, Neurog1*) and neural (*Nestin, Sox1, Pax2*) differentiation supporting our conclusion about cNCC and neural differentiation defects in *Neil1*- and *Neil2*-deficient mESCs. The results are presented in Figure 6---figure supplement 2 and Figure 7---figure supplement 2.

[^1]: These authors contributed equally to this work.
